清肝化瘀口服液对介入治疗肝癌患者免疫功能及肿瘤转移影响的研究
|
摘要
原发性肝细胞癌(Hepatocellular Carcinoma, HCC)以下简称原发性肝癌,为世界常见难治的恶性肿瘤之一,由于其发病隐匿,确诊时常常失去了手术治疗的机会。经导管动脉内化疗栓塞术(transcather arterial chemoembolization, TACE)又称肝动脉化疗栓塞治疗,是目前公认为对不能手术切除的原发性肝癌的安全、有效、可反复的首选常规治疗方法,它近期疗效显著,可使肿瘤缩小,症状缓解,并有效杀灭肿瘤细胞,在一定时间内控制肿瘤的生长,延长患者生存时间。但由于碘油栓塞以及大量化疗药物短时间进入体内,造成肝组织缺血缺氧,导致机体整体功能的严重损害,改善TACE治疗后原发性肝癌患者的免疫功能,降低术后肿瘤的复发率,延长生存期,成为提高治疗效果的关键。
中草药是天然的生物反应调节物质(Biological response modulation substance,BRMs),可以提高机体免疫力,与机体免疫系统、内分泌系统、神经系统等相互影响与协调,共同维持生命机制的稳定与平衡,具有辅助抗肿瘤,减少介入治疗的毒副作用等功能。
原发性肝癌患者多有免疫功能的异常,常伴有免疫抑制因子的表达升高和/或免疫促进因子表达水平的降低。研究表明患者外周血中IL-2及肿瘤坏死因子-α(TNF-α)水平变化与原发性肝癌密切相关。IL-2为重要的细胞免疫促进因子,具有明显的抗肿瘤作用,sIL-2R为免疫抑制因子,其在血循环中与IL-2结合从而封闭阻断了IL-2的作用。TNF-α具有多种生物学功能,对多种肿瘤细胞与正常细胞具有直接的细胞毒作用,并能介导炎症与免疫反应。
血管内皮生长因子(vascular endothelial growth factor, VEGF)是一种重要的血管生长因子,对血管内皮细胞的增殖、水解基膜、迁移和血管构建的调控作用较强,且特异性高。HCC为典型的多血管肿瘤,生长迅速,且极易发生肝内血管浸润及癌栓形成,疗效欠佳。研究表明,人肝细胞癌中有较强VEGF的表达,且VEGF的表达与原发性肝癌的生长和转移密切相关。环氧合酶-2(cyclooxygenase-2, COX-2)作为前列腺素生物合成过程中的一个重要限速酶,在多种肿瘤的发生发展和转移中起重要作用,其表达受细胞内外多种因素的影响。COX - 2在肿瘤中的作用机制作主要包括①抗凋亡作用;②促进肿瘤血管生成;③增强肿瘤细胞的侵袭性;④炎性刺激及免疫抑制作用;⑤对前致癌物的氧化转化作用。有研究表明,在原发性肝癌中COX-2呈高表达,原发性肝癌患者外周血中VEGF及COX-2水平的检测对判断原发性肝癌转移和复发有着重要的价值,对指导临床治疗,改善患者预后有重要的意义。
TACE治疗使得大量化疗药物短时间进入体内以及碘油栓塞,会造成肝组织缺血缺氧,导致机体整体功能的严重损害。如何改善TACE治疗后原发性肝癌患者的免疫功能,降低术后肿瘤的复发率,改善生存质量,延长生存期,是提高治疗效果的关键。
目的
本研究对TACE术后患者给予中药联合治疗,检测中药清肝化瘀口服液对原发性肝癌患者肝动脉化疗栓塞( transcatheter arterial chemoembolization, TACE)术后血液中CD3+, CD4+, CD4+/CD8+、自然杀伤细胞(natural killer cell, NK)及甲胎蛋白(alpha-fetoproteins,AFP)的变化,测定患者外周血中VEGF及COX-2的含量变化,观察患者综合指标,探讨中药对TACE术后机体免疫功能、肿瘤转移潜能及生存质量的影响,揭示清肝化瘀口服液对抑制肝癌细胞增殖、降低肝癌细胞COX-2、VEGF表达的作用,从免疫学和原发性肝癌转移两方面阐明清肝化瘀口服液联合介入治疗在原发性肝癌治疗中提高免疫力,减轻毒副作用,抑制肿瘤转移等方面,进一步探讨中药治疗原发性肝癌的作用以及作用靶点,从而增强病人免疫功能、提高原发性肝癌患者的生存期,为中药的临床研究提供试验依据。
方法
1病例选择:随机选取我院2006年2月至2007年2月间住院原发性肝癌患者60例,男38例,女22例,年龄48～65岁,平均56.3±7.7岁。所有患者均符合以下诊断标准:①术后组织学检查为原发性肝细胞肝癌;②影像学检查有明确实性占位;③甲胎蛋白(AFP)>200μg/L,持续4周以上。临床分期按2001年9月中国抗癌协会肝癌专业委员会制定标准对患者分期,Ⅰ期8例,Ⅱ期42例,Ⅲ期10例。
2试验分组:随机将患者分为试验组及对照组。试验组即TACE+中药组:原发性肝癌患者30例,男20例,女10例,平均年龄55.5±8.7岁,其中Ⅰ期5例,Ⅱ期19例,Ⅲ期6例。对照组即单纯TACE组:原发性肝癌患者30例,男18例,女12例,平均年龄56.9±7.9岁,其中Ⅰ期3例,Ⅱ期23例,Ⅲ期4例。
3标本采集:分别于介入术前1天和介入术后第28天早晨空腹静脉采集样血5 ml,分装不抗凝管与肝素抗凝管,不抗凝管4℃,2500 r/min离心10分钟,分离血清,-30℃保存待测;抗凝管直接送检。
4外周血T细胞亚群的检测:选用三色荧光标记的免抗试剂直接荧光染色,采用流式细胞术进行测定两组患者治疗前后外周血CD3+, CD4+, CD4+/CD8+、NK细胞活性。
5血清细胞因子检测:双抗体夹心酶联免疫吸附法(ELISA法)检测两组患者治疗前后血清中TNF-α和IL-2水平。
6 ELISA法检测两组患者治疗前后外周血中VEGF蛋白水平表达。
7 RT-PCR法检测两组患者治疗前后外周血有核细胞中COX-2基因表达。
8测定TACE+中药组及单纯TACE组患者治疗前后AFP水平
9检测两组患者治疗后病灶变化及肝外转移情况: CT和/或彩色多谱勒超声检查肿瘤最大直径乘以其垂直直径与治疗前比较;CT和/或超声及胸片检查,随访观察肺、骨、脑及淋巴结的转移情况。
10对两组患者治疗后的疗效进行判定:按照WHO制定的实体瘤客观评价标准进行判定及分析。判定标准为:①完全缓解为病灶全部吸收;②部分缓解为病灶部分缓解;③无变化为病灶无变化;④病情进展为病灶进展。
11对两组患者治疗后生活质量进行评价:根据卡氏功能状态(Karnosky performance status, KPS)评分,以治疗后较治疗前增加>10分为改善,减少>10分为下降,变化≤10分为稳定。
12统计学分析:数据处理采用SPSS 13.0统计软件。计量资料以均数±标准差( X±S)表示,组间比较采用成组设计的t检验;同组治疗前后比较采用配对t检验;计数资料比较采用X2检验,以P<0.05为差异有统计学意义。
结果
1 TACE+中药组及单纯TACE组两组患者T细胞亚群和NK细胞比较:两组患者治疗前外周血CD4+、CD8+、CD4+/CD8+及NK测定值无显著性差异,两组具有可比性;原发性肝癌介入治疗后28日时,检测患者外周血中CD3+, CD4+, CD4+/CD8+、NK细胞测定值分别为0.23±0.18,0.18±0.04,1.12±0.46及10.68±3.01,经清肝化瘀口服液联合介入治疗后患者外周血中CD3+, CD4+, CD4+/CD8+、NK细胞测定值分别为0.55±0.11, 0.35±0.09,1.65±0.29及31.07±6.56,结果显示经清肝化瘀口服液联合介入治疗后外周血中CD3+, CD4+, CD4+/CD8+、NK细胞较单纯介入治疗组明显增高(P<0.05),提示清肝化瘀口服液可有效增强原发性肝癌介入治疗患者的细胞免疫。
2原发性肝癌患者介入治疗前后血清TNF-α和IL-2水平比较:患者经介入治疗后TNF-α浓度明显下降(P<0.05),IL-2浓度增高。
3 TACE+中药组及单纯TACE组介入治疗前后外周血细胞因子TNF-α及IL-2的比较:两组患者治疗前外周血细胞因子TNF-α及IL-2测定值无显著性差异,两组具有可比性;TACE+中药组介入治疗后外周血细胞因子TNF-α含量为10.85±1.67,显著低于单纯TACE组的13.56±1.55,说明清肝化瘀口服液可协助TACE有效降低TNF-α表达量(P<0.05);TACE+中药组介入治疗后外周血细胞因子IL-2含量为32.83±3.03,高于单纯TACE组的28.05±2.95,说明清肝化瘀口服液可协助TACE有效增强IL-2的表达(P<0.05)。
4 TACE+中药组及单纯TACE组介入治疗前后外周血中VEGF表达的比较:两组患者治疗前,血清VEGF表达量无显著性差异,两组具有可比性;原发性肝癌患者介入治疗后28日时,检测患者外周血中VEGF表达量为456.08±175.49,经清肝化瘀口服液联合介入治疗后患者外周血中VEGF表达量为207.49±93.22,结果显示清肝化瘀口服液联合治疗可有效降低介入治疗后增高的VEGF(P<0.05)。
5 TACE+中药组及单纯TACE组介入治疗前后外周血有核细胞中COX-2表达比较:治疗前,两组患者COX-2阳性表达率及表达量无显著性差异,两组具有可比性;介入治疗后28日时,检测TACE+中药组与单纯TACE治疗组患者外周血有核细胞中COX-2表达量比较发现,经清肝化瘀口服液联合介入治疗后患者外周血有核细胞中COX-2表达阳性率为47.77%,明显低于单纯TACE治疗组的55.69%(P<0.05),同时表达量也低于单纯TACE治疗组。提示清肝化瘀口服液可有效降低原发性肝癌介入治疗患者外周血有核细胞中COX-2的表达。
6原发性肝癌患者中药清肝化瘀口服液联合介入治疗后患者中有6例发生肝外转移,转移率为20%,单纯TACE组发生肝外转移14例,肝外转移率为43.3%,二者差异有统计学意义(P<0.05)。
7原发性肝癌患者TACE+中药组,部分缓解患者24例,有效率为80%,单纯TACE治疗组部分缓解者12例,有效率为40%,两组间差异有统计学意义(P<0.05)。
8原发性肝癌患者中药清肝化瘀口服液联合介入治疗后KPS评分后判定,生活质量改善者13例,改善率为43.3%,单纯TACE组生活质量改善者6例,改善率仅20%,两组间差异有统计学意义(P<0.05)。
结论
1 TACE+中药组NK细胞下降的幅度低于单纯TACE治疗组,CD3+, CD4+, CD4+/CD8+的值高于单纯TACE治疗组说明清肝化瘀口服液对化疗引起的细胞免疫抑制有一定的保护作用。
2 TACE+中药组外周血中VEGF及COX-2表达显著降低,说明TACE联合应用清肝化瘀口服液在抑制肿瘤内血管生成、防止肿瘤转移中具有重要作用。
3 TACE+中药组在瘤体客观疗效及临床症状的缓解率上均优于单纯TACE治疗组,说明化疗介入联合应用清肝化瘀口服液治疗原发性肝癌在瘤体缩小、缓解临床症状方面优于单纯西医治疗。
4治疗后两组病例生活质量的比较,TACE+中药组优于单纯TACE治疗组,提示中西医结合治疗原发性肝癌可以改善或提高患者的生活质量。
5 TACE+中药组AFP值下降显著,与单纯TACE组有统计学意义,提示化疗介入配合清肝化瘀口服液可以较好地降低血中AFP水平。
6从化疗的不良反应如肝功能损害出现的情况看,TACE+中药组低于单纯TACE治疗组,说明清肝化瘀口服液辅助西医化疗介入治疗原发性肝癌在减轻化疗毒副作用方面明显优于单纯西医治疗。
Hepatocellular Carcinoma (HCC), called hepatama for short, is one of an incurable malignant tumor in world. Because of its hiding morbidity, the opportunity for operating therapy is often missing. Transcather arterial chemoembolization (TACE), also called hepatic arterial chemoembolization (HACE), is considered a secure, effective and repeatable first selecting conventional therapy for the inoperable hepatama. Its curative effect is significant in the near future. TACE can deflate the tumor, relieve the symptom and kill the tumor cells. It can control the growth of the tumor in a short time and prolong the live time of the patients. Because a large quantity of chemo medicine comes into body, the liver tissue will be ischemic and hypoxia and the allomeric function of organism is damaged severely. Improving the immunological function of the hepatama patients after TACE, cutting down the recurrence rate of the tumor and prolonging the live time have been the key point of the therapeutic efficacy.
The traditional Chinese medicine is the natural medicine. It can improve the immunity of the organism and it can coordinate and influence each other with immune system, endocrine system and nervous system. They maintain the stabilization and balance of the life mechanism, help to resist tumor growth and decrease the side effect of the interventional therapy in common.
The patients with hepatoma often have immunological function abnormality. The expression of immune suppressive factors increases and the expression of immune enhancive factors decreases. The study suggested that the change of TNF-αand IL-2 in the blood of patients with HCC had close correlation to HCC. IL-2 is an important cell immune enhancive factor and it has significant effects to resist tumor. sIL-2R is an immune suppressive factor. It can combine to the IL-2 in blood circulation and hold up the effects of IL-2. TNF-αhas many biological function and has intimate cell toxic action to many tumor cells and normal cells. It can also mediate inflammation and immune reaction.
Vascular endothelial growth factor is an important vascular growth factor. It has strong effects on proliferation of vascular endothelial cell, hydrolization of basal lamina, cell immigration and vascular construction. It also has high specificness. HCC is a typical tumor with vascularity. It grows quickly and the vascular infiltration among the liver is easily to happen. The therapeutic effect is below the mark. There is study showed that the expression of VEGF was significantly in hepatoma cells and it has close relation to the growth and metastasis of HCC. Cyclooxygenase-2 is an important rate-limiting enzyme in the biosynthesis process of prostaglandin and it has essential effects in the genesis, development and metastasis of lots of tumors. There is study showed that the expression of COX-2 was high in hepatoma and the expressive level of VEGF and COX-2 in the peripheral blood had important value in judging the metastasis and recurrence of hepatoma. It also had significance in guiding clinical therapy and improving prognosis.
Objective
In this study, the traditional Chinese medicine had been given to the HCC patients after TACE. The change of CD3+, CD4+, CD4+/CD8+, NK cell and alpha-fetoprotein (AFP) in blood were detected after the therapy with QingGanHuaYu orally taking liquid in HCC patients after TACE. The content of VEGF and COX-2 in peripheral blood was also examined and the composite index of the patients was observed. Through the above research, the influence of traditional Chinese medicine on the immune function, the potentiality of tumor metastasis and living quality was discussed. This study revealed the effects of QingGanHuaYu orally taking liquid on the suppression of the proliferation of hepatoma cells and the decreasing of the expression of VEGF. This study illuminated the contribution of QingGanHuaYu orally taking liquid to the therapy of HCC from both immunology and HCC metastasis sides. It can improve the immunity, lessen side effects and inhibit tumor metastasis and so on. This study also discussed the effects of traditional Chinese medicine and its targets and provided experimental basis to the clinical study of the traditional Chinese medicine.
Methods
1 Patients selection: The patients with HCC was randomly selected from the forth hospital of Hebei Medical University from 2006.2 to 2007.2. Among the patients, there were 38 males and 22 females and the age of the patients was from 48-65 and the average age was 56.3±7.7. All the patients were consistent with the following diagnostic code: (1) the result of histology examination was HCC; (2) imaging examination identifies the position; (3) AFP>200μg/L. According to Chinese liver cancer cooperation meeting staging standard, stage I were 8 cases, stage II were 42 cases and stage III were 10 cases.
2 Experimental grouping: Divide the patients randomly into experimental group and control group:The experimental group is TACE with traditional Chinese medicine therapy. Among the 30 cases of PHC patients, there were 20 males and 10 females. The average age was 55.5±8.7. The patients in stage I were 5 cases, stage II 19 cases and stage III 6 cases.The control group is merely TACE group. Among the 30 cases of PHC patients, there were 18 males and 12 females. The average age was 56.9±7.9. The patients in stage I were 3 cases, stage II 23 cases and stage III 4 cases.
3 Specimen collecting: Blood sample 5ml was collected 1 day before and 28 days after the intervention in the morning on an empty stomach. The blood was stuff into non-anticoagulation and anticoagulation tubes respectively. The centrifugalization was carried out at 4oC in 2500r/min for 10min. The serum and blood plasma was divided and preserved at -30oC.
4 The examination of T cell subgroup: The CD3+, CD4+, CD4+/CD8+ and NK cell activity in peripheral blood were examined through flow cytometry with the antibody labeled by triad colour fluorescent before and after the therapy in the two patients groups.
5 The examination of cytokine in serum: The serum level of TNF-αand IL-2 of the patients were detected by double antibody sandwich enzyme linked immunosorbent assay (ELISA) method.
6 The VEGF level in peripheral blood of the two patients group was examined through ELISA method.
7 The expression of COX-2 in gene level in blood karyocyte was detected by RT-PCR method in the two patients group before and after therapy.
8 The examine of AFP in two patients group was performed.
9 The detection of the tumor change and outside liver metastasis: the maximum level diameter and vertical diameter was determined by CT or multicolor ultrasonic examination by Doppler’s method. Calculated the volume of the tumor and compared them before and after therapy. The outside metastasis to lung, bone, brain and absorbent gland was detected by CT or sternite.
10 The therapeutic effect assessment of the two groups after therapy: The assessment and analysis were based on the solid tumor objective evaluation criterion enacted by WHO. The assessment standard was as follow: (1) complete remission means the tumor is absorbed completely; (2) partial remission means the tumor is absorbed partly; (3) no change means the tumor has no change; (4) pathogenetic condition advancement means the tumor increases.
11 The evaluation of life quality of the two groups: The evaluation was based on the Karnosky performance status (KPS). Improving means after therapy the score increases beyond 10; descending means after therapy the score decreases beyond 10; stabilizing means the score changes in 10.
12 Statistical analysis: the data processing was carried out by SPSS 13.0 software. Measurement data was expressed as X±S. The compare between groups was using T test. The enumeration data was compared by X2 test. Ranked data was compared by rank-sum test. P<0.05 means the difference has statistical significance.
Results
1 The comparison of T cell subgroup and NK cell between two groups:the examine values of CD3+, CD4+, CD4+/CD8+ and NK cell had no significant difference before the therapy. Compared with the simple TACE group, the TACE with QingGanHuaYu orally taking liquid group had low CD3+ value (P<0.05)、CD4+ value (P<0.05) and the CD4+/CD8+ value also decreased (P<0.05).
2 The comparison of TNF-αand IL-2 level in serum between prior and circa of the interventional therapy: compared with prior therapy, the TNF-αlevel decreased (P<0.05) and the IL-2 level (P<0.05) increased significantly after therapy.
3 The comparison of TNF-αand IL-2 level in serum between the two groups: compared with the simple TACE group(13.56±1.55), the TNF-αlevel(10.85±1.67) decreased (P<0.05); and the IL-2 level (P<0.05) increased significantly in the TACE with QingGanHuaYu orally taking liquid group(32.83±3.03) compared with the simple group(28.05±2.95).
4 After the interventional therapy, the VEGF level in serum and the expression of COX-2 in the blood karyocyte Compared with before the interventional therapy, the difference had statistical significance (P<0.05). The comparison of VEGF expression between the two groups: the VEGF level in TACE with QingGanHuaYu orally taking liquid group (207.49±93.22) was significant lower than that of simple TACE group (456.08±175.49) (P<0.05).
5 The comparison of COX-2 in peripheral blood karyocyte between two groups: the value of COX-2 in TACE with QingGanHuaYu orally taking liquid group was 47.77%, significant lower than that of simple TACE group 55.69%. The difference had statistical significance (P<0.05).
6 In the TACE with QingGanHuaYu orally taking liquid group, there were 6 patients had metastasis outside liver and the metastasis rate was 20%. In the simple TACE group, there were 14 patients had metastasis outside liver and the metastasis rate was 43.3%. The difference between the two group had statistical significance (P<0.05).
7 In the TACE with QingGanHuaYu orally taking liquid group, there were 24 patients had partial remission and the effective rate was 80%. In the simple TACE group, there were 12 patients had partial remission and the effective rate was 40%. The difference between the two group had statistical significance (P<0.05).
8 According to the KPS evaluation standard, there were 13 patients had life quality improvement and the improving rate was 43.3% in the TACE with QingGanHuaYu orally taking liquid group. There were 6 patients had life quality improvement and the improving rate was only 20% in the simple TACE group. The difference between the two group had statistical significance (P<0.05).
Conclusion
1 In the TACE with QingGanHuaYu orally taking liquid therapy group, the NK cell decreasing extent of NK cell is lower than that of simple TACE therapy group and the value of CD3+, CD4+, CD4+/CD8+ were higher than that of simple TACE therapy group. So, QingGanHuaYu orally taking liquid has protection to the cell immunity of the HCC patients after chemo.
2 The expression of VEGF and COX-2 in peripheral blood degraded significantly in the TACE with QingGanHuaYu orally taking liquid therapy group. Using QingGanHuaYu orally taking liquid after TACE therapy can inhibit the angiogenesis in tumor.
3 In the TACE with QingGanHuaYu orally taking liquid therapy group, the objective tumor curative effect and the relief rate of clinical symptom were better than the simple TACE group. The TACE therapy combined with QingGanHuaYu orally taking liquid can deflate the volume of the tumor and relieve the clinical symptom.
4 When it comes to the comparison of the life quality, the patients accepted TACE with QingGanHuaYu orally taking liquid therapy were living better than those of accepting the simple TACE therapy. So, combined treatment of traditional Chinese medicine and western medicine toHCC can improve the patients’life quality significantly.
5 In the TACE with QingGanHuaYu orally taking liquid therapy group, the value of AFP in peripheral blood descended largely. When compared with the simple TACE therapy group, the difference had statistical significance. The TACE therapy combined the QingGanHuaYu orally taking liquid therapy can degrade the level of AFP in peripheral blood of the patients with HCC.
6 On the adverse effect of the TACE therapy such as liver function lesion, in the TACE with QingGanHuaYu orally taking liquid therapy group, it is less than that of the simple TACE therapy group. QingGanHuaYu orally taking liquid can reduce and lessen the side effects after the TACE therapy in the patients with HCC.
中草药是天然的生物反应调节物质(Biological response modulation substance,BRMs),可以提高机体免疫力,与机体免疫系统、内分泌系统、神经系统等相互影响与协调,共同维持生命机制的稳定与平衡,具有辅助抗肿瘤,减少介入治疗的毒副作用等功能。
原发性肝癌患者多有免疫功能的异常,常伴有免疫抑制因子的表达升高和/或免疫促进因子表达水平的降低。研究表明患者外周血中IL-2及肿瘤坏死因子-α(TNF-α)水平变化与原发性肝癌密切相关。IL-2为重要的细胞免疫促进因子,具有明显的抗肿瘤作用,sIL-2R为免疫抑制因子,其在血循环中与IL-2结合从而封闭阻断了IL-2的作用。TNF-α具有多种生物学功能,对多种肿瘤细胞与正常细胞具有直接的细胞毒作用,并能介导炎症与免疫反应。
血管内皮生长因子(vascular endothelial growth factor, VEGF)是一种重要的血管生长因子,对血管内皮细胞的增殖、水解基膜、迁移和血管构建的调控作用较强,且特异性高。HCC为典型的多血管肿瘤,生长迅速,且极易发生肝内血管浸润及癌栓形成,疗效欠佳。研究表明,人肝细胞癌中有较强VEGF的表达,且VEGF的表达与原发性肝癌的生长和转移密切相关。环氧合酶-2(cyclooxygenase-2, COX-2)作为前列腺素生物合成过程中的一个重要限速酶,在多种肿瘤的发生发展和转移中起重要作用,其表达受细胞内外多种因素的影响。COX - 2在肿瘤中的作用机制作主要包括①抗凋亡作用;②促进肿瘤血管生成;③增强肿瘤细胞的侵袭性;④炎性刺激及免疫抑制作用;⑤对前致癌物的氧化转化作用。有研究表明,在原发性肝癌中COX-2呈高表达,原发性肝癌患者外周血中VEGF及COX-2水平的检测对判断原发性肝癌转移和复发有着重要的价值,对指导临床治疗,改善患者预后有重要的意义。
TACE治疗使得大量化疗药物短时间进入体内以及碘油栓塞,会造成肝组织缺血缺氧,导致机体整体功能的严重损害。如何改善TACE治疗后原发性肝癌患者的免疫功能,降低术后肿瘤的复发率,改善生存质量,延长生存期,是提高治疗效果的关键。
目的
本研究对TACE术后患者给予中药联合治疗,检测中药清肝化瘀口服液对原发性肝癌患者肝动脉化疗栓塞( transcatheter arterial chemoembolization, TACE)术后血液中CD3+, CD4+, CD4+/CD8+、自然杀伤细胞(natural killer cell, NK)及甲胎蛋白(alpha-fetoproteins,AFP)的变化,测定患者外周血中VEGF及COX-2的含量变化,观察患者综合指标,探讨中药对TACE术后机体免疫功能、肿瘤转移潜能及生存质量的影响,揭示清肝化瘀口服液对抑制肝癌细胞增殖、降低肝癌细胞COX-2、VEGF表达的作用,从免疫学和原发性肝癌转移两方面阐明清肝化瘀口服液联合介入治疗在原发性肝癌治疗中提高免疫力,减轻毒副作用,抑制肿瘤转移等方面,进一步探讨中药治疗原发性肝癌的作用以及作用靶点,从而增强病人免疫功能、提高原发性肝癌患者的生存期,为中药的临床研究提供试验依据。
方法
1病例选择:随机选取我院2006年2月至2007年2月间住院原发性肝癌患者60例,男38例,女22例,年龄48～65岁,平均56.3±7.7岁。所有患者均符合以下诊断标准:①术后组织学检查为原发性肝细胞肝癌;②影像学检查有明确实性占位;③甲胎蛋白(AFP)>200μg/L,持续4周以上。临床分期按2001年9月中国抗癌协会肝癌专业委员会制定标准对患者分期,Ⅰ期8例,Ⅱ期42例,Ⅲ期10例。
2试验分组:随机将患者分为试验组及对照组。试验组即TACE+中药组:原发性肝癌患者30例,男20例,女10例,平均年龄55.5±8.7岁,其中Ⅰ期5例,Ⅱ期19例,Ⅲ期6例。对照组即单纯TACE组:原发性肝癌患者30例,男18例,女12例,平均年龄56.9±7.9岁,其中Ⅰ期3例,Ⅱ期23例,Ⅲ期4例。
3标本采集:分别于介入术前1天和介入术后第28天早晨空腹静脉采集样血5 ml,分装不抗凝管与肝素抗凝管,不抗凝管4℃,2500 r/min离心10分钟,分离血清,-30℃保存待测;抗凝管直接送检。
4外周血T细胞亚群的检测:选用三色荧光标记的免抗试剂直接荧光染色,采用流式细胞术进行测定两组患者治疗前后外周血CD3+, CD4+, CD4+/CD8+、NK细胞活性。
5血清细胞因子检测:双抗体夹心酶联免疫吸附法(ELISA法)检测两组患者治疗前后血清中TNF-α和IL-2水平。
6 ELISA法检测两组患者治疗前后外周血中VEGF蛋白水平表达。
7 RT-PCR法检测两组患者治疗前后外周血有核细胞中COX-2基因表达。
8测定TACE+中药组及单纯TACE组患者治疗前后AFP水平
9检测两组患者治疗后病灶变化及肝外转移情况: CT和/或彩色多谱勒超声检查肿瘤最大直径乘以其垂直直径与治疗前比较;CT和/或超声及胸片检查,随访观察肺、骨、脑及淋巴结的转移情况。
10对两组患者治疗后的疗效进行判定:按照WHO制定的实体瘤客观评价标准进行判定及分析。判定标准为:①完全缓解为病灶全部吸收;②部分缓解为病灶部分缓解;③无变化为病灶无变化;④病情进展为病灶进展。
11对两组患者治疗后生活质量进行评价:根据卡氏功能状态(Karnosky performance status, KPS)评分,以治疗后较治疗前增加>10分为改善,减少>10分为下降,变化≤10分为稳定。
12统计学分析:数据处理采用SPSS 13.0统计软件。计量资料以均数±标准差( X±S)表示,组间比较采用成组设计的t检验;同组治疗前后比较采用配对t检验;计数资料比较采用X2检验,以P<0.05为差异有统计学意义。
结果
1 TACE+中药组及单纯TACE组两组患者T细胞亚群和NK细胞比较:两组患者治疗前外周血CD4+、CD8+、CD4+/CD8+及NK测定值无显著性差异,两组具有可比性;原发性肝癌介入治疗后28日时,检测患者外周血中CD3+, CD4+, CD4+/CD8+、NK细胞测定值分别为0.23±0.18,0.18±0.04,1.12±0.46及10.68±3.01,经清肝化瘀口服液联合介入治疗后患者外周血中CD3+, CD4+, CD4+/CD8+、NK细胞测定值分别为0.55±0.11, 0.35±0.09,1.65±0.29及31.07±6.56,结果显示经清肝化瘀口服液联合介入治疗后外周血中CD3+, CD4+, CD4+/CD8+、NK细胞较单纯介入治疗组明显增高(P<0.05),提示清肝化瘀口服液可有效增强原发性肝癌介入治疗患者的细胞免疫。
2原发性肝癌患者介入治疗前后血清TNF-α和IL-2水平比较:患者经介入治疗后TNF-α浓度明显下降(P<0.05),IL-2浓度增高。
3 TACE+中药组及单纯TACE组介入治疗前后外周血细胞因子TNF-α及IL-2的比较:两组患者治疗前外周血细胞因子TNF-α及IL-2测定值无显著性差异,两组具有可比性;TACE+中药组介入治疗后外周血细胞因子TNF-α含量为10.85±1.67,显著低于单纯TACE组的13.56±1.55,说明清肝化瘀口服液可协助TACE有效降低TNF-α表达量(P<0.05);TACE+中药组介入治疗后外周血细胞因子IL-2含量为32.83±3.03,高于单纯TACE组的28.05±2.95,说明清肝化瘀口服液可协助TACE有效增强IL-2的表达(P<0.05)。
4 TACE+中药组及单纯TACE组介入治疗前后外周血中VEGF表达的比较:两组患者治疗前,血清VEGF表达量无显著性差异,两组具有可比性;原发性肝癌患者介入治疗后28日时,检测患者外周血中VEGF表达量为456.08±175.49,经清肝化瘀口服液联合介入治疗后患者外周血中VEGF表达量为207.49±93.22,结果显示清肝化瘀口服液联合治疗可有效降低介入治疗后增高的VEGF(P<0.05)。
5 TACE+中药组及单纯TACE组介入治疗前后外周血有核细胞中COX-2表达比较:治疗前,两组患者COX-2阳性表达率及表达量无显著性差异,两组具有可比性;介入治疗后28日时,检测TACE+中药组与单纯TACE治疗组患者外周血有核细胞中COX-2表达量比较发现,经清肝化瘀口服液联合介入治疗后患者外周血有核细胞中COX-2表达阳性率为47.77%,明显低于单纯TACE治疗组的55.69%(P<0.05),同时表达量也低于单纯TACE治疗组。提示清肝化瘀口服液可有效降低原发性肝癌介入治疗患者外周血有核细胞中COX-2的表达。
6原发性肝癌患者中药清肝化瘀口服液联合介入治疗后患者中有6例发生肝外转移,转移率为20%,单纯TACE组发生肝外转移14例,肝外转移率为43.3%,二者差异有统计学意义(P<0.05)。
7原发性肝癌患者TACE+中药组,部分缓解患者24例,有效率为80%,单纯TACE治疗组部分缓解者12例,有效率为40%,两组间差异有统计学意义(P<0.05)。
8原发性肝癌患者中药清肝化瘀口服液联合介入治疗后KPS评分后判定,生活质量改善者13例,改善率为43.3%,单纯TACE组生活质量改善者6例,改善率仅20%,两组间差异有统计学意义(P<0.05)。
结论
1 TACE+中药组NK细胞下降的幅度低于单纯TACE治疗组,CD3+, CD4+, CD4+/CD8+的值高于单纯TACE治疗组说明清肝化瘀口服液对化疗引起的细胞免疫抑制有一定的保护作用。
2 TACE+中药组外周血中VEGF及COX-2表达显著降低,说明TACE联合应用清肝化瘀口服液在抑制肿瘤内血管生成、防止肿瘤转移中具有重要作用。
3 TACE+中药组在瘤体客观疗效及临床症状的缓解率上均优于单纯TACE治疗组,说明化疗介入联合应用清肝化瘀口服液治疗原发性肝癌在瘤体缩小、缓解临床症状方面优于单纯西医治疗。
4治疗后两组病例生活质量的比较,TACE+中药组优于单纯TACE治疗组,提示中西医结合治疗原发性肝癌可以改善或提高患者的生活质量。
5 TACE+中药组AFP值下降显著,与单纯TACE组有统计学意义,提示化疗介入配合清肝化瘀口服液可以较好地降低血中AFP水平。
6从化疗的不良反应如肝功能损害出现的情况看,TACE+中药组低于单纯TACE治疗组,说明清肝化瘀口服液辅助西医化疗介入治疗原发性肝癌在减轻化疗毒副作用方面明显优于单纯西医治疗。
Hepatocellular Carcinoma (HCC), called hepatama for short, is one of an incurable malignant tumor in world. Because of its hiding morbidity, the opportunity for operating therapy is often missing. Transcather arterial chemoembolization (TACE), also called hepatic arterial chemoembolization (HACE), is considered a secure, effective and repeatable first selecting conventional therapy for the inoperable hepatama. Its curative effect is significant in the near future. TACE can deflate the tumor, relieve the symptom and kill the tumor cells. It can control the growth of the tumor in a short time and prolong the live time of the patients. Because a large quantity of chemo medicine comes into body, the liver tissue will be ischemic and hypoxia and the allomeric function of organism is damaged severely. Improving the immunological function of the hepatama patients after TACE, cutting down the recurrence rate of the tumor and prolonging the live time have been the key point of the therapeutic efficacy.
The traditional Chinese medicine is the natural medicine. It can improve the immunity of the organism and it can coordinate and influence each other with immune system, endocrine system and nervous system. They maintain the stabilization and balance of the life mechanism, help to resist tumor growth and decrease the side effect of the interventional therapy in common.
The patients with hepatoma often have immunological function abnormality. The expression of immune suppressive factors increases and the expression of immune enhancive factors decreases. The study suggested that the change of TNF-αand IL-2 in the blood of patients with HCC had close correlation to HCC. IL-2 is an important cell immune enhancive factor and it has significant effects to resist tumor. sIL-2R is an immune suppressive factor. It can combine to the IL-2 in blood circulation and hold up the effects of IL-2. TNF-αhas many biological function and has intimate cell toxic action to many tumor cells and normal cells. It can also mediate inflammation and immune reaction.
Vascular endothelial growth factor is an important vascular growth factor. It has strong effects on proliferation of vascular endothelial cell, hydrolization of basal lamina, cell immigration and vascular construction. It also has high specificness. HCC is a typical tumor with vascularity. It grows quickly and the vascular infiltration among the liver is easily to happen. The therapeutic effect is below the mark. There is study showed that the expression of VEGF was significantly in hepatoma cells and it has close relation to the growth and metastasis of HCC. Cyclooxygenase-2 is an important rate-limiting enzyme in the biosynthesis process of prostaglandin and it has essential effects in the genesis, development and metastasis of lots of tumors. There is study showed that the expression of COX-2 was high in hepatoma and the expressive level of VEGF and COX-2 in the peripheral blood had important value in judging the metastasis and recurrence of hepatoma. It also had significance in guiding clinical therapy and improving prognosis.
Objective
In this study, the traditional Chinese medicine had been given to the HCC patients after TACE. The change of CD3+, CD4+, CD4+/CD8+, NK cell and alpha-fetoprotein (AFP) in blood were detected after the therapy with QingGanHuaYu orally taking liquid in HCC patients after TACE. The content of VEGF and COX-2 in peripheral blood was also examined and the composite index of the patients was observed. Through the above research, the influence of traditional Chinese medicine on the immune function, the potentiality of tumor metastasis and living quality was discussed. This study revealed the effects of QingGanHuaYu orally taking liquid on the suppression of the proliferation of hepatoma cells and the decreasing of the expression of VEGF. This study illuminated the contribution of QingGanHuaYu orally taking liquid to the therapy of HCC from both immunology and HCC metastasis sides. It can improve the immunity, lessen side effects and inhibit tumor metastasis and so on. This study also discussed the effects of traditional Chinese medicine and its targets and provided experimental basis to the clinical study of the traditional Chinese medicine.
Methods
1 Patients selection: The patients with HCC was randomly selected from the forth hospital of Hebei Medical University from 2006.2 to 2007.2. Among the patients, there were 38 males and 22 females and the age of the patients was from 48-65 and the average age was 56.3±7.7. All the patients were consistent with the following diagnostic code: (1) the result of histology examination was HCC; (2) imaging examination identifies the position; (3) AFP>200μg/L. According to Chinese liver cancer cooperation meeting staging standard, stage I were 8 cases, stage II were 42 cases and stage III were 10 cases.
2 Experimental grouping: Divide the patients randomly into experimental group and control group:The experimental group is TACE with traditional Chinese medicine therapy. Among the 30 cases of PHC patients, there were 20 males and 10 females. The average age was 55.5±8.7. The patients in stage I were 5 cases, stage II 19 cases and stage III 6 cases.The control group is merely TACE group. Among the 30 cases of PHC patients, there were 18 males and 12 females. The average age was 56.9±7.9. The patients in stage I were 3 cases, stage II 23 cases and stage III 4 cases.
3 Specimen collecting: Blood sample 5ml was collected 1 day before and 28 days after the intervention in the morning on an empty stomach. The blood was stuff into non-anticoagulation and anticoagulation tubes respectively. The centrifugalization was carried out at 4oC in 2500r/min for 10min. The serum and blood plasma was divided and preserved at -30oC.
4 The examination of T cell subgroup: The CD3+, CD4+, CD4+/CD8+ and NK cell activity in peripheral blood were examined through flow cytometry with the antibody labeled by triad colour fluorescent before and after the therapy in the two patients groups.
5 The examination of cytokine in serum: The serum level of TNF-αand IL-2 of the patients were detected by double antibody sandwich enzyme linked immunosorbent assay (ELISA) method.
6 The VEGF level in peripheral blood of the two patients group was examined through ELISA method.
7 The expression of COX-2 in gene level in blood karyocyte was detected by RT-PCR method in the two patients group before and after therapy.
8 The examine of AFP in two patients group was performed.
9 The detection of the tumor change and outside liver metastasis: the maximum level diameter and vertical diameter was determined by CT or multicolor ultrasonic examination by Doppler’s method. Calculated the volume of the tumor and compared them before and after therapy. The outside metastasis to lung, bone, brain and absorbent gland was detected by CT or sternite.
10 The therapeutic effect assessment of the two groups after therapy: The assessment and analysis were based on the solid tumor objective evaluation criterion enacted by WHO. The assessment standard was as follow: (1) complete remission means the tumor is absorbed completely; (2) partial remission means the tumor is absorbed partly; (3) no change means the tumor has no change; (4) pathogenetic condition advancement means the tumor increases.
11 The evaluation of life quality of the two groups: The evaluation was based on the Karnosky performance status (KPS). Improving means after therapy the score increases beyond 10; descending means after therapy the score decreases beyond 10; stabilizing means the score changes in 10.
12 Statistical analysis: the data processing was carried out by SPSS 13.0 software. Measurement data was expressed as X±S. The compare between groups was using T test. The enumeration data was compared by X2 test. Ranked data was compared by rank-sum test. P<0.05 means the difference has statistical significance.
Results
1 The comparison of T cell subgroup and NK cell between two groups:the examine values of CD3+, CD4+, CD4+/CD8+ and NK cell had no significant difference before the therapy. Compared with the simple TACE group, the TACE with QingGanHuaYu orally taking liquid group had low CD3+ value (P<0.05)、CD4+ value (P<0.05) and the CD4+/CD8+ value also decreased (P<0.05).
2 The comparison of TNF-αand IL-2 level in serum between prior and circa of the interventional therapy: compared with prior therapy, the TNF-αlevel decreased (P<0.05) and the IL-2 level (P<0.05) increased significantly after therapy.
3 The comparison of TNF-αand IL-2 level in serum between the two groups: compared with the simple TACE group(13.56±1.55), the TNF-αlevel(10.85±1.67) decreased (P<0.05); and the IL-2 level (P<0.05) increased significantly in the TACE with QingGanHuaYu orally taking liquid group(32.83±3.03) compared with the simple group(28.05±2.95).
4 After the interventional therapy, the VEGF level in serum and the expression of COX-2 in the blood karyocyte Compared with before the interventional therapy, the difference had statistical significance (P<0.05). The comparison of VEGF expression between the two groups: the VEGF level in TACE with QingGanHuaYu orally taking liquid group (207.49±93.22) was significant lower than that of simple TACE group (456.08±175.49) (P<0.05).
5 The comparison of COX-2 in peripheral blood karyocyte between two groups: the value of COX-2 in TACE with QingGanHuaYu orally taking liquid group was 47.77%, significant lower than that of simple TACE group 55.69%. The difference had statistical significance (P<0.05).
6 In the TACE with QingGanHuaYu orally taking liquid group, there were 6 patients had metastasis outside liver and the metastasis rate was 20%. In the simple TACE group, there were 14 patients had metastasis outside liver and the metastasis rate was 43.3%. The difference between the two group had statistical significance (P<0.05).
7 In the TACE with QingGanHuaYu orally taking liquid group, there were 24 patients had partial remission and the effective rate was 80%. In the simple TACE group, there were 12 patients had partial remission and the effective rate was 40%. The difference between the two group had statistical significance (P<0.05).
8 According to the KPS evaluation standard, there were 13 patients had life quality improvement and the improving rate was 43.3% in the TACE with QingGanHuaYu orally taking liquid group. There were 6 patients had life quality improvement and the improving rate was only 20% in the simple TACE group. The difference between the two group had statistical significance (P<0.05).
Conclusion
1 In the TACE with QingGanHuaYu orally taking liquid therapy group, the NK cell decreasing extent of NK cell is lower than that of simple TACE therapy group and the value of CD3+, CD4+, CD4+/CD8+ were higher than that of simple TACE therapy group. So, QingGanHuaYu orally taking liquid has protection to the cell immunity of the HCC patients after chemo.
2 The expression of VEGF and COX-2 in peripheral blood degraded significantly in the TACE with QingGanHuaYu orally taking liquid therapy group. Using QingGanHuaYu orally taking liquid after TACE therapy can inhibit the angiogenesis in tumor.
3 In the TACE with QingGanHuaYu orally taking liquid therapy group, the objective tumor curative effect and the relief rate of clinical symptom were better than the simple TACE group. The TACE therapy combined with QingGanHuaYu orally taking liquid can deflate the volume of the tumor and relieve the clinical symptom.
4 When it comes to the comparison of the life quality, the patients accepted TACE with QingGanHuaYu orally taking liquid therapy were living better than those of accepting the simple TACE therapy. So, combined treatment of traditional Chinese medicine and western medicine toHCC can improve the patients’life quality significantly.
5 In the TACE with QingGanHuaYu orally taking liquid therapy group, the value of AFP in peripheral blood descended largely. When compared with the simple TACE therapy group, the difference had statistical significance. The TACE therapy combined the QingGanHuaYu orally taking liquid therapy can degrade the level of AFP in peripheral blood of the patients with HCC.
6 On the adverse effect of the TACE therapy such as liver function lesion, in the TACE with QingGanHuaYu orally taking liquid therapy group, it is less than that of the simple TACE therapy group. QingGanHuaYu orally taking liquid can reduce and lessen the side effects after the TACE therapy in the patients with HCC.
引文
1 张智坚, 吴孟超. 射频热凝固治疗在肝癌治疗中的应用. 国外医学外科学分册, 2000, 27(4):194-196
2 陈曙光, 赵海涛, 张宁, 等. 以 TACE 为主综合治疗不能手术切除的原发性肝癌, 肿瘤防治研究, 2005, 32(8):505-506
3 唐树尧, 解亦斌, 姜涛, 等. RFA 和 TACE 联合应用对原发性肝癌的疗效分析. 哈尔滨医科大学学报, 2005, 39(2):183-187
4 闭永浩, 方富义, 莫钦国, 等. 栓塞化疗合并注射无水乙醇治疗原发性肝癌(附 112 例报告). 广西医学, 2005, 27(12):1929-1931
5 李忱瑞, 李文波, 李清华, 等. 原发性肝癌术前动脉化疗栓塞的疗效评价.癌症进展杂志, 2006, 4(2):168-171
6 叶胜龙. 重视原发性肝癌的规范化治疗. 中华肝脏病杂志, 2004, 12:449
7 Sun HC, Tang ZY. Preventive treatments for recurrence aftercurative resection of hepatocellular carcinoma: A literature review of randomized control trials. World J Gastroenterol, 2003, 9:635
8 Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha forhepatocellular carcinoma patients with major portal veinthrombosis or distant metastasis. Cancer, 2000, 88:1986
9 刘鹏飞, 刘荣华, 徐荷, 等. 原发性肝癌术后预防性 TACE 的意义(附433 例病例随访). 中华肝胆外科杂志, 2005, 11(2):81-82
10 Ikeda Y, Kajiyama K, Adachi E, et al. Early recurrence after surgery of hepatocellular carcinoma. Hepatogast roenterology, 1995, 42:469-472
11 Hashimoto T , Nakamura H , Hori S , et al . Hepatocellular carcinoma : efficacy of t ranscat heter oily chemoembolization in relationto macroscopic and microscopic pat terns of tumor growt h among100 patient s wit h partial hepatectomy. Cardiovasc Intervent Radiol , 1995, 18:82-86
12 Chung JW, Park J H , Han J K, et al . Hepatic tumors : predisposing factors for complication of t ranscat her oily chemoembolization. Radiology , 1996 , 198 (1) :33-40
13 Caturelli E , Siena DA , Fusilli s , et al . Transcat heter arterialchemoembolization for hepatocellularcarcinoma in patients with cirrhosis : evaluation of damage to nontumorous liver tissue long term prospective study . Radiology , 2000 , 21 (5) :123-128
14 Kat sumori T, Fujita M,Takahashi, et al. Effective segmental chemoembolization of advanced hepatocellular carcinoma with tumor t hrombus in the portal vein. Cardiovasc Intervent Radiol , 1995 , 18 (4) : 2172221
15 陈晓明, 罗鹏飞, 邵培坚, 等. 肝癌节段性栓塞化疗与常规栓塞化疗的比较研究. 中华放射学杂志,2000 , 34 (4) : 271-273
16 Ikeda K, Kumada H, Saitoh S, et al . Effect of repeatd t ranscat heter arterial embolization on the survival time in patients with hepatocellular carcinoma : an analysis by the cox proportional hazard model. Cancer , 1991 , 68 (10) : 2150-2154
17 Kamada K, Nakanishi T, Kitamoto M , et al . Longterm prognosis of patient s undergoing t ranscat heter arterial chemoembolization for unresectable hepatocellular carcinoma : comparison of cisplatin lipiodol suspension and doxorubicin hydrocholoride emusion. J Vasc Interv Radiol, 2001 , 12(7) :847-854
18 卢伟, 李彦豪, 李祖国, 等. 小剂量和常规剂量化疗药物经导管动脉内化疗栓塞后肝细胞坏死及凋亡的比较研究. 中华放射学杂志, 2003 , 37 (3) : 232-237
19 程楷, 池宏杰, 张为忠. 肾上腺素在肝癌动脉栓塞化疗中的应用. 中国肿瘤临床, 2002 , 29 (1) : 71-72
20 Lotze MT , Finn OJ . Recent advance in cellular immunology : implications for immunity to cancer. Immunol Today , 1990;11(6) :190
21 巴德年主编. 当代免疫学技术与应用. 北京:北京医科大学中国协和医科大学联合出版社出版, 1998;11
22 黄辉,俞红,林云璐. CD4 + T 细胞的抗瘤作用. 国外医学免疫学分册, 2000;23(1):51
23 金伯泉主编. 细胞和分子免疫学. 北京世界图书出版公司,1995;8
24 乔刚, 李汉臣, 席红军, 等. 食管癌患者手术前后细胞免疫的变化. 新乡医学院学报, 1999;16(4):308
25 彭贵勇, 蔡景修, 袁爱力. 肝癌患者免疫功能变化及影响因素. 重庆医学, 1999; 28(6):421
26 侯恩存,王新,恋祖平, 等. 肝动脉化疗栓塞术对肝癌患者细胞免疫功能的影响. 实用肿瘤学杂志, 2006; 20(5):372-374
27 李彩霞,李传福,曹驰. 肝癌患者 TACE 前后细胞免疫状态变化. 山东大学学报(医学版). 2003; 41(5):553-555
28 Kamohara Y, Kanematsu T. Treatment of liver cancer: current status and future prospectives. Gan to Kagaku Kyoho, 2000, 27(7):987-992
29 郭红梅. 原发性肝癌介入治疗前后血清 TNF-α,SIL-2R 水平检测的临床意义. Huaihai Med,2003,21(5):364-365
30 陈飞,侯芳玉. 肿瘤坏死因子与 SIDS. 国外医学· 免疫学分册,1992,4:179-189
31 Wu S,Boyer CM,Whitaker Rs,et al. Tuor necrosis factor for ovarian cancer; Monokine induction of tumor cell proliferation and tumor necrosis factor a expression. Cancer Res,1993,535:1939
32 Rey A, Klein B, Zagury D, et al. Diminished interleukin-2 activityproduction in cancer patients bearing solid tumors and its relationship with natural killer cells. Immunol Lett, 1983, 6(3):175~178
33 Matsunaga H, Kuwahara Y, Kusugami K, et al. Natural killer, lymphokine- activated killer and interferon-gamma producing activities of peripheral blood- and regional lymph node-mononuclear cells in 23 cases of colorectal cancer. Gastroenterol Jpn, 1988 ,23(5):527~533
34 Kusugami K, Matsuura T, Kawase T, et al. Interleukin 2 and interferon- gamma activities of mononuclear cells from regional lymph nodes in patients with gastric cancer. Gastroenterol Jpn, 1990 ,25(3):306~313
35 Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science, 1990 ,248(4961):1349~1356
36 Fischer JR,Schindel M,Bulzebruck H,et al. Long-term survival In small cell lung cancer patients is correlated with high interleukin-2 secretion at diagnosis.J Cancer Res Clin Oncol,2000,126:730~733
1 Gospdarowicz D,Abran Ram JA,Schillin J.Isolation and characterization of Avascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells.Proc Natl Acad Sci USA,1989,86:7311-7315
2 Ferrare N,Davis S T.Biology properties of the vascular endothelial growth factor familyof proteins.Endocr Rev,1997,18(1):4-25
3 Benjamin LE,Golijanin D,Itin A,et al.Selective ablation of i m mature blood vesselsin establish human tumors follows vascular endothelial growth factor withdraw.J Clin Invest,1999,103(2):159-165
4 Dvorak HF,Nagy JA,Feng D,et al.Vascular permeability factor/vascular endothelial growth factor and significance of microvascular permeability in angiogenesis.Curr Top Microbiol,1999,237(2):97-132
5 Jones A,Fujiyama C.Angiogenesis in urological malignancy prognostic indicator and therapeutic target.BJU International,1999,83(5):535-555
6 Folkman J . Clinical applications of research on angiogenesis〔see comments〕. N Eng1 J Med , 1995 ,333(26) :1757～1763
7 An FQ,Matsuda M,Fujii H,et al.Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma.J Cancer Res Olin Onco1,2000,126(3):153-160
8 Yamaguchi R,Yano H,lemura A,et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology, 1998, 28:68-77
9 Poon RT,Lau C,Yu WC,et al.High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma:a prospective study.Oncol Rep, 2004, 11(5): 1077-1084
10 柏林,吴永明,尹艳茹.肝癌患者血清 VEGF 的表达及临床意义. 第一军医大学分校学报, 2002,25(1):7-10
11 Brown LF , Berse B , Jackman R ,et al . Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol ,1995 ,26(11):86～91
12 Suzuki K, Hayashi N , Miyamoto Y, et al. Expression of vascular permeability factor/ vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res , 1996 , 56(13):3004-3009
13 Poon R T , Fan S T , Lo C M ,et al . Int rahepatic recurrence after curative resection of hepatocellular carcinoma. Long-term results of t reatment and prognostic factors . Ann Surg , 1999 , 229(1):216-222
14 Poon R T , Ng I O , Lau C , et al . Serum vascular endot helial growth factor predict s venous invasion in hepatocellular carcinoma : a prospective study . Ann Surg , 2001 , 233 (1):227-235
15 Goldstein HM, Wallnce S, Anderson JH, et al. Transcatheterem bolism of abdom inal tum ors Radiology, 1976, 120:539
16 葛宁灵,林芷英.影响介入治疗中晚期肝癌疗效的病理因素分析.国外医学·肿瘤学分册,1996,23:173-174
17 郭吉刚,郭顺林,杜富全,等.原发性肝癌 TACE 治疗前后血清 VEGF含量的变化.中华临床医学影像杂志,2003,14:181-183
18 Smith WL, Garavito RM, Dewitt DL, et al. Prostaglandin endoperoxide synthases cyclooxygenases-1 and-2. J Biol Chem, 1996, 271 (52): 33157-33160
19 Eberhart CE,Coffey RJ,Radhika A,et al.Up regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994,107:1183-1188
20 Koga H,Sakisaka S,Ohishe M,et al.Expression of cyclooxygenase-2 inhuman hepatocellular carcinoma:relevance to tumor dedifferentiation. Hepatology ,1999,29:688-696
21 Zhang BX, Chen XP, Yu HP, et al. Significance of cyclo-oxygenase-2 expression in human primary hepatocellular carcinoma. Chin J Exp Surg ,2004,21(3):305-306
22 Kondo M,Yamamoto H,Nagano H,et al.Increased expression if cox-2 in nontumor liver tissue is associated with shorter diseasefree survival in patients with hepatocellular carcinoma.Clin Cancer Res, 1999, 5:4005-4012 Murata H,Kawano S,Tsuji S,et al.Cyclooxygenase-2 over expression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol, 1996,94:51
1 李天晓,樊青霞,王瑞林.恶性肿瘤介入治疗学.郑州:河南科学技术出版社,2000:233
2 张天泽,徐光炜.肿瘤学. 第 2 版.天津:天津科学技术出版社, 2005:1602
3 Geschwind JF. Chemoembolization for hepatocellular carcinoma: where does the truth lie. J Vasc Interv Radiol,2002,13(10):991–994
4 张中华,陈衍智. 中药配合肝动脉化疗栓塞治疗肝癌临床观察. 实用肿瘤学杂志,2005,19(3):211-213
5 周炳刚,孙靖中,景生虹,等.中西医结合治疗中晚期肝癌 26 例疗效观察.新中医. 2002,3(11):37～38
6 邬晓东,金学军,刘淑梅,等.中药护肝软坚方对Ⅱ、Ⅲ期原发性肝癌肝动脉化疗栓塞增效减毒作用观察.北京中医药大学学报2003,26(1):67～68
7 俞世唐,斯艳阳,张为强,等.介入合并中医药治疗 362 例中晚期肝癌疗效评估.肿瘤研究与临床 2002,14(4):279～280
8 董明娥,白小娟,冯居秦,等.健脾益肾法配合介入治疗晚期肝癌36 例.陕西中医 2002,23(10):905
9 黄国贤,张蓓,张亚奇,等.中药防治肝癌介入治疗后肝储备功能损伤的临床研究.新医学 2003,34(4):221～222
10 何辉,王晓红,何东初.介入化疗联合复方苦参注射液治疗中晚期肝癌 30 例.中西医结合肝病杂志 2004,14(4):243～244
11 杨金祖,杨金坤,郑坚,等.中西医结合防治肝癌介入术后栓塞综合征的临床观察.上海中医药杂志 2004,38(9):11～12
12 姜新红,刘政,姚长清,等.健脾生血丸治疗肝癌介入术后不良反应的临床观察.中国中西医结合杂志 2003,23(11):866
13 汤钊酞,钦伦秀,孙惠川,等.肝癌复发转移的研究.中华普通外科杂志 2000,15(9):517～520
14 徐晓玉,严鹏科,陈刚,等.川穹嗪对小鼠肺癌血管生长和 VEGF表达的抑制.中国药理学通报 2004,20(2):151～154
15 冯刚,孔庆志,黄冬生,等.慧该仁注射液对小鼠移植性 s180 肉瘤血管形成抑制的作用.肿瘤防治研究 2004,31(4):229～230
16 林钧华,郭伟剑.健脾理气方联合介入疗法治疗肝癌远处转移 25 例临床观察.中医杂志 2005,46(l):26～28
17 陈宁.中晚期原发性肝癌中药应用规律.陕西中医,1995,16(2):87
18 Stockland AH, Walser EM, Paz-Fumagalli R, et al. Preoperative chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: influence of emergent versus elective procedures on patient survival and tumor recurrence rate. Cardiovasc Intervent Radiol,2007,30(5):888-893
19 徐伯平,张亚奇,李升平,等。化瘀健脾疏肝法对改善肝癌术后肝功能的影响。中国中西医结合杂志, 2001,21(10):742-743
20 姚树坤,殷飞,王娜。清肝化瘀方药对原发性肝癌患者的疗效及对细胞免疫功能的影响。临床荟萃, 2006,(18):1300-1302
1 吴孟超, 沈锋, 吴东. 原发性肝癌的外科治疗. 中华肝胆外科杂志. 2005, 11(2):75-77
2 Schmassmann A. Nonsurgical therapies for hepatocellular and cholangiocellular carcinoma. Swiss Surg. 1999, 5(3):116-121
3 Guan YS, Liu Y. Interventional treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2006, 5(4):495-500
4 Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987,163:345-351
5 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003, 37:429-442
6 李桂杰, 周祝谦, 王连祥. 经肝动脉化疗栓塞术. 山东医药. 2006, 46(17):87-88
7 林含舜, 曹美萍, 李军苗. 肝动脉化疗栓塞治疗原发性肝癌. 实用医学杂志. 2003, 19(10):1178-1179
8 Goldstein HM, Wallace S, Anderson JH, et al. Transcatheter occlusion of abdominall tumors. Radiology. 1976, 120(3):539-545
9 O’Suilleabhain CB, Poon RT, Yong JL, et al. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg. 2003, 90(3):325-331
10 Barone M, Ettorre GC, Ladisa R, et al. Transcatheter arterial chemoembolization (TACE) in treatment of hepatocelluar carcinoma. Hepatogastroenterology. 2003, 50(49):183-187
11 Yamada R, Kishi K, Sato M, et al. Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer. World J Surg. 1995, 19(6):795-800
12 Lo CM, Ngan H, Tso WK. Randomized controlled trial of tansarterial lipiodol chemoembolization for unresectable hepatocellular carcinama.Hepatology. 2002, 35(5):1164-1171
13 Gunji T, Kawauchi N, Akahane M, et al. Long-term outcome of transcatheter arterial chemoembolization with autologous blood clot for unresectalbe hepatocellular carcinoma. Int J Oncol. 2002, 21(2):427-432
14 孙健, 张彤, 王捷. 肝癌的TACE治疗. 国外医学外科学分册. 2005, 32(2):84-88
15 Trinchet JC, Ganne-Carrie N, Beangrand M. Intraarterial chemoembolization in patients with hepaocellular carcinoma. Hepatogastro Enterology. 1998, 45(Suppl 3):1242-1243
16 Ochiai T, Sonoyama T, Hironaka T, et al. Hepatectomy with chemoembolization for treatment of hepatocellular carcinoma. Hepatogastroenterology. 2003, 50(51):750-755
17 Hanazaki K, Kajikawa S, Shimozaxa N, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 2000, 191(4):381-388
18 Tanaka K, Shimada H, Togo S, et al. Use of tanscatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology, 1999, 46(2):1083-1088
19 Asahara T, Itamoto T, Katayam K, et al. Adjuvant hepatic arterial infusion chemotheraphy after radical hepatectomy for hepatocellular carcinoma-results of long-term follow-up. Hepatogastroenterology. 1999, 46(2):1042-1048
20 Saccheri S, Lovaria A, Sangiovanni A, et al. Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J Vasc Interv Radiol. 2002, 13(10):995-999
21 Li JQ. Clinical and laboratory study on cut-margin of hepatocellular carcinoma. J Gastroenterol Hepatol. 2000, 15(Suppl):157
22 Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment andprongostic factors. Ann Surg. 1999, 229(2):216-222
23 Li YH, Wang CS, Liao LY, et al. Long-term survival of Taicanese patients with hepatocellular carcinoma after combination therapy with tanscatheter arterial chemoembolization and percutaneous ethanol injection. J Formos Med Assoc. 2003, 102(3):141-146
24 Bloomston M, Binitie O, Fraiji E, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg. 2002, 68(9):827-831
25 Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolizal followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003, 9(6):557-563
26 Ishikura S, Ogino T, Furuse J, et al. Radiotherapy after tanscatheter arterial chemoembolization for patient with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol. 2002, 25(2):189-193
27 Shiomi M, Kamiya J, Naqino M, et al. Hepatocellular carcinoma with biliary tumor thrombi: aggressive operative approach after appropriate preoperative management. Surgery. 2001, 129(6):692-698
28 Hu J, Pi Z, Yu MY, et al. Obstructive jaundice caused by tumor embolization from hepatocellular carcinoma. Am Surg. 1999, 65(5):406-410
29 Fukuda S, Okuda K, Imamura M, et al. Surgical resection combined with chemothraphy from advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery. 2002, 131(3):300-310
30 高宗恩, 张承勋, 庞闽厦, 等. 肝癌供血的特点及其在介入治疗中的意义. 2001, 9(12):1449-1451
31 茅国新, 于志坚, 张一心, 等. 经导管肝动脉和B超引导下经细针门静脉双重化疗栓塞治疗原发性肝癌. 中华肿瘤杂志. 2002, 24(4):391-393
32 Ng KK, Poon RT. Current treatment strategy for hepatocellular carcinoma. Saudi Med J. 2007, 28(9):1330-1338
33 蔡东顺, 贾朝阳. 经肝动脉栓塞化疗与无水乙醇消融术联合治疗小肝癌. 现代医用影像学. 2005, 14(5):220-221
34 胡大武, 陈君辉, 伍海翔, 等. 肝动脉化疗栓塞结合经皮肝穿刺瘤内注射醋酸治疗原发性肝癌的疗效观察. 介入放射学杂志. 2004, 13(1):53-55
35 江怡, 顾庆. 肝动脉栓塞化疗和超声引导下介入综合治疗肝肿瘤. 上海医学影像. 2002, 11(3):228-229,231
36 曹玮, 王执民, 张洪新. 介入性热化疗治疗肝癌. 医师进修杂志. 2004; 27(3):55-56
37 Hui KM. Current approaches in the transcriptional-guided gene therapy of human hepatocellular carcinoma. Curr Opin Mol Ther. 2007; 9(4):378-384
38 官泳松, 孙龙, 周翔平, 等. 重组人p53腺病毒基因局部注射联合肝动脉化疗栓塞治疗原发性肝癌. 世界华人消化杂志. 2005, 13(1):125-127
39 Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002, 94(6):1747-1752
40 肖承江, 郑丽吟, 蒋晓红. 肝动脉栓塞化疗对肝损害的观察(附100例分析). 中华放射学杂志. 1997, 31(11):777-779
41 施海彬, 冯耀良. 合并门静脉癌栓的原发性肝癌的影像学特征及其介入治疗. 临床放射学杂志. 1997, 16(2):111-113
42 Katsumori T, Fujita M, Takahashi T, et al. Effective segmental chemoembolization of advanced hepatocellular carcinoma with tumor thrombus in the portal vein. Cardiovasc Intervent Radiol. 1995, 18(4):217-221
43 陈晓明, 罗鹏飞, 邵培坚, 等. 肝癌节段性栓塞化疗与常规栓塞化疗的比较研究. 中华放射学杂志. 2000, 34(4):271-273
44 骆训武, 蓝琳, 张亚力, 等. 腺苷蛋氨酸在肝动脉插管栓塞化疗术后的护肝作用. 中华消化杂志. 2002, 22(11):680
45 Okuhama Y, Shiraishi M, Higa T, et al. Protective effects of ulinastatin against ischemia-reperfusion injury. J Surg Res. 1999,82(1):34-42
46 Kobayashi H, Shinohara H, Gotho J, et al. Anti-metastatic therapy byurinary trypsin inhibitor in combination with an anti-cancer agent. Br J Cancer. 1995, 72(5):1131-1137
47 叶华, 王捷, 张建龙. 乌司他丁在肝动脉栓塞化疗中的应用. 中华肝胆外科杂志. 2002, 8(4):249-250
48 陈徐贤, 张蓓, 张亚奇, 等. 中药防治肝癌化疗栓塞术后肝储备功能损害的临床研究. 癌症. 2002, 21(5):547-549
1 Nq KK, Poon RT. Current treatment strategy for hepatocellular carcinoma. Saudi Med J. 2007, 28(9):1330-1338
2 Chen XX, Zhang B, Zhang YQ, et al. Treatment of hepatic functional reserve injury after TACE in hepatocellular carcinoma with Chinese herbal medicines. Ai Zheng. 2002, 21(5):547-549
3 Feng YL, Ling CQ, Li B. Clinical study on integrative medicine for preventing and treating post-transcatheter arterial chemoembolization. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005, 25(6):534-536
4 陈徐贤, 张蓓, 张亚奇, 等. 健脾活血中药对肝癌肝动脉化疗栓塞术后综合征的影响. 新中医. 2006, 38(7):57-58
5 肖承江, 郑丽吟, 蒋晓红. 肝动脉栓塞化疗对肝损害的观察(附100例分析). 中华放射学杂志. 1997, 31(11):777-779
6 狄灵,杨成志,刘润侠,等. 参芪扶正注射液治疗原发性肝癌栓塞化疗综合征的临床研究. 现代肿瘤医学. 2004, 12(5):473-474
7 李仲启, 傅汉中, 魏国强, 等. 参麦注射液配合肝动脉化疗栓塞治疗肝癌临床疗效观察. 中国肿瘤临床与康复. 2005, 12(1):64-65
8 李杰,孙桂芝. 肝康冲剂配合肝动脉介入治疗原发性肝癌的临床研究. 医学理论与实践. 1998, 11(8):341-343
9 李翠静, 许祖闪. 肝动脉化疗栓塞后免疫或中药综合治疗肝癌108例观察. 肿瘤防治杂志. 2003, 10(11):1209-1210
10 于有涛,申宝忠. 蛇莲胶囊对介入治疗原发性肝癌患者免疫功能的影响. 中国肿瘤. 2003, 12(1):59-60
11 张绪平, 易玉海, 金鹏, 等. 恶性肿瘤介入疗法常用中药制剂抗癌机制国内研究概况. 实用医药杂志. 2006, 23(2):232-234
12 程剑华, 吴万垠, 刘伟胜, 等. 莪术油肝动脉灌注栓塞治疗原发性肝癌
17 例. 世界华人消化杂志. 1999, 7(1):92
13 冯敢生, 郑传胜, 张彦舫. 中药白芨胶栓塞治疗肝癌的应用研究. 中国肿瘤. 1997, 6(4):10-12
14 凌昌全, 李琦. 中药经肝动脉介入治疗原发性肝癌的现状、存在问题及前景. 中医杂志. 2002, 43(1):69-71
15 贺用和, 韩静. 中药制剂在原发性肝癌肝动脉化疗栓塞术治疗中的应用研究进展. 中国中医药信息杂志. 2006, 13(12):95-97
16 顾伟, 韩克起. 中医药在肝癌介入治疗中的临床应用. 肝脏. 2003, 8(4):59-61
17 陆浩, 周健生, 徐逊, 等. 康莱特注射液联合肝动脉化学栓塞治疗中晚期原发性肝癌疗效观察. 中原医刊. 2006, 33(23):3-4
18 钱军, 秦叔逵. 抗癌新药——榄香烯的药理及临床. 中国肿瘤临床. 1996, 23(6):453-455
19 周洪语, 侯菊生, 罗其中. 榄香烯抗肿瘤作用机制的研究进展. 中国肿瘤临床. 2000, 27(5):392-394
20 梁宇闯, 高珩, 林坚, 等. 经肝动脉插管灌注榄香烯乳治疗中晚期肝癌的观察. 右江民族医学院学报. 2004, 26(2):200-201
21 崔永安, 左小东, 秦叔逵, 等. 华蟾素抗肿瘤作用的临床研究. 江苏临床医学杂志. 2002, 6(5):505-508
22 孙中杰, 潘承恩, 王国俊. 华蟾素配合 TACE 治疗肝癌的临床观察. 肿瘤防治研究. 2002, 29(1):67-68
23 陈庆强, 王昌俊, 卢秋红. 羟基喜树碱肝动脉栓塞及灌注治疗晚期原发性肝癌. 中国肿瘤临床. 2000, 27(8):620-621
24 陈杰, 张先稳. 艾迪注射液对荷瘤小鼠的抗瘤效应及免疫调节作用. 徐州医学院学报. 2005, 25(3):208-210
25 袁洪新, 于志坚. 艾迪注射液联合肝动脉介入治疗原发性肝癌. 临床肿瘤学杂志. 2005, 10(1):64-66
26 李琦, 范忠泽, 李先茜, 等. 去甲斑蝥素微球介入治疗大鼠肝癌疗效及其机制研究. 中西医结合学报. 2006, 4(4):378-383
27 杨林, 孟茂斌, 官泳松, 等. 中医中药在肿瘤介入治疗中的应用. 2006, 21(3):646-647
28 司维柯, 李鹏, 王源, 等. 苦参碱抗人肝癌细胞株HepG2的作用及其机制研究. 国外医学临床生物化学与检验学分册. 2003, 24(5):288-290
29 王俊学, 王国俊, 蔡雄, 等. 氧化苦参碱及甘草甜素对小鼠肝细胞凋亡的影响. 第二军医大学学报, 1999, 20(4):222-224
30 许相儒, 蒋纪恺. 苦参及其生物碱抗肿瘤活性研究进展. 中国中西医结合杂志. 1998, 8(5):314-316
31 梁建新, 曾文铤, 朱科伦, 等. 苦参碱联合介入化疗栓塞治疗中晚期肝癌疗效观察. 广州医药. 2005, 36(3):45-47
32 莉萍, 蒋纪恺, 谭安, 等. 苦参碱对K562细胞端粒酶活性细胞周期的影响. 中华肿瘤杂志. 1998, 20(5):328
33 于绍军, 朱英杰, 高峰. 岩舒注射液治疗晚期肝癌临床观察. 华北煤炭医学院学报. 2000, 2(5):552
34 朱晓锋, 李国安. 岩舒注射液联合介入化疗栓塞治疗中晚期肝癌的研究. 现代中西医结合杂志. 2006, 15(4):431-432
35 Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [ stronger neo-minophagen C (SNMC) ] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology. 2002, 62(11):94-100
36 Rossi T, Castelli M, Zandomeneghi G, et al. Selectivity of action of glycyrrhizin derivatives on the growth of MCF27 and HEP22 cells. Anticancer Res. 2003, 23(5A):3813-3818
37 Miyaji C, Miyakawa R, Watanabe H, et al. Mechanisms underlying the activation of cytotoxic function mediated by hepatic lymphocytes following the administration of glycyrrhizin. Int Immunopharmacol. 2002, 2(8):1079-1086
38 Lu W, Li Y, He X, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patientswith cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Hepatogastroenterology. 2003, 50(54):2079-2083
39 张伟, 叶孟, 金伟. 复方甘草酸苷在原发性肝癌TACE术后的应用. 浙江中西医结合杂志. 2006, 16(4):210-211
40 袁国荣. 鸦胆子油乳联合介入化疗为主治疗局部晚期非小细胞肺癌40例 临 床 研 究 —— 附 单 用 介 入 化 疗 38 例 对 照 . 浙 江 中 医 杂 志 . 2005,15(1):13-15
41 马杰津. 抗癌药物鸦胆子的研究进展. 医学文选. 2001, 20(3):378-379
42 李英, 徐功立, 李颖, 等. 鸦胆子油乳诱导白血病U937细胞凋亡的实验研究.中华血液学杂志. 2004, 25(6):381-382
43 Kleibl Z, Raisova M, No Votny J, et al. Apoptosis and its importance in the development and therapy of tumors. Sb Lek. 2002, 103(1):1-3
44 李笑弓, 向勋义, 李建功, 等. 鸦胆子油静脉乳对人肾癌影响的实验研究. 临床泌尿外科杂志. 1998, 13(2):82-87
45 李文志, 冯汝就. 鸦胆子油乳注射液联合TACE治疗原发性肝癌的临床疗效观察. 中药材. 2006, 29(6):632-633
46 吴万垠, 励雁峰. 健脾理气方对人乙型肝炎病毒转基因小鼠不同时相血清黄曲霉素B1-白蛋白加成物水平的影响. 中西医结合肝病杂志. 1996, 6(2):17-18
47 卜平, 陈齐鸣. 实脾法防治TAE胃肠损害并发症的临床研究. 中西医结合肝病杂志. 1996, 6(4):16-17
48 陈群雄. 参三金粉对肝癌介入化疗后的作用. 中医药研究. 1998, 14(3):34-35
2 陈曙光, 赵海涛, 张宁, 等. 以 TACE 为主综合治疗不能手术切除的原发性肝癌, 肿瘤防治研究, 2005, 32(8):505-506
3 唐树尧, 解亦斌, 姜涛, 等. RFA 和 TACE 联合应用对原发性肝癌的疗效分析. 哈尔滨医科大学学报, 2005, 39(2):183-187
4 闭永浩, 方富义, 莫钦国, 等. 栓塞化疗合并注射无水乙醇治疗原发性肝癌(附 112 例报告). 广西医学, 2005, 27(12):1929-1931
5 李忱瑞, 李文波, 李清华, 等. 原发性肝癌术前动脉化疗栓塞的疗效评价.癌症进展杂志, 2006, 4(2):168-171
6 叶胜龙. 重视原发性肝癌的规范化治疗. 中华肝脏病杂志, 2004, 12:449
7 Sun HC, Tang ZY. Preventive treatments for recurrence aftercurative resection of hepatocellular carcinoma: A literature review of randomized control trials. World J Gastroenterol, 2003, 9:635
8 Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha forhepatocellular carcinoma patients with major portal veinthrombosis or distant metastasis. Cancer, 2000, 88:1986
9 刘鹏飞, 刘荣华, 徐荷, 等. 原发性肝癌术后预防性 TACE 的意义(附433 例病例随访). 中华肝胆外科杂志, 2005, 11(2):81-82
10 Ikeda Y, Kajiyama K, Adachi E, et al. Early recurrence after surgery of hepatocellular carcinoma. Hepatogast roenterology, 1995, 42:469-472
11 Hashimoto T , Nakamura H , Hori S , et al . Hepatocellular carcinoma : efficacy of t ranscat heter oily chemoembolization in relationto macroscopic and microscopic pat terns of tumor growt h among100 patient s wit h partial hepatectomy. Cardiovasc Intervent Radiol , 1995, 18:82-86
12 Chung JW, Park J H , Han J K, et al . Hepatic tumors : predisposing factors for complication of t ranscat her oily chemoembolization. Radiology , 1996 , 198 (1) :33-40
13 Caturelli E , Siena DA , Fusilli s , et al . Transcat heter arterialchemoembolization for hepatocellularcarcinoma in patients with cirrhosis : evaluation of damage to nontumorous liver tissue long term prospective study . Radiology , 2000 , 21 (5) :123-128
14 Kat sumori T, Fujita M,Takahashi, et al. Effective segmental chemoembolization of advanced hepatocellular carcinoma with tumor t hrombus in the portal vein. Cardiovasc Intervent Radiol , 1995 , 18 (4) : 2172221
15 陈晓明, 罗鹏飞, 邵培坚, 等. 肝癌节段性栓塞化疗与常规栓塞化疗的比较研究. 中华放射学杂志,2000 , 34 (4) : 271-273
16 Ikeda K, Kumada H, Saitoh S, et al . Effect of repeatd t ranscat heter arterial embolization on the survival time in patients with hepatocellular carcinoma : an analysis by the cox proportional hazard model. Cancer , 1991 , 68 (10) : 2150-2154
17 Kamada K, Nakanishi T, Kitamoto M , et al . Longterm prognosis of patient s undergoing t ranscat heter arterial chemoembolization for unresectable hepatocellular carcinoma : comparison of cisplatin lipiodol suspension and doxorubicin hydrocholoride emusion. J Vasc Interv Radiol, 2001 , 12(7) :847-854
18 卢伟, 李彦豪, 李祖国, 等. 小剂量和常规剂量化疗药物经导管动脉内化疗栓塞后肝细胞坏死及凋亡的比较研究. 中华放射学杂志, 2003 , 37 (3) : 232-237
19 程楷, 池宏杰, 张为忠. 肾上腺素在肝癌动脉栓塞化疗中的应用. 中国肿瘤临床, 2002 , 29 (1) : 71-72
20 Lotze MT , Finn OJ . Recent advance in cellular immunology : implications for immunity to cancer. Immunol Today , 1990;11(6) :190
21 巴德年主编. 当代免疫学技术与应用. 北京:北京医科大学中国协和医科大学联合出版社出版, 1998;11
22 黄辉,俞红,林云璐. CD4 + T 细胞的抗瘤作用. 国外医学免疫学分册, 2000;23(1):51
23 金伯泉主编. 细胞和分子免疫学. 北京世界图书出版公司,1995;8
24 乔刚, 李汉臣, 席红军, 等. 食管癌患者手术前后细胞免疫的变化. 新乡医学院学报, 1999;16(4):308
25 彭贵勇, 蔡景修, 袁爱力. 肝癌患者免疫功能变化及影响因素. 重庆医学, 1999; 28(6):421
26 侯恩存,王新,恋祖平, 等. 肝动脉化疗栓塞术对肝癌患者细胞免疫功能的影响. 实用肿瘤学杂志, 2006; 20(5):372-374
27 李彩霞,李传福,曹驰. 肝癌患者 TACE 前后细胞免疫状态变化. 山东大学学报(医学版). 2003; 41(5):553-555
28 Kamohara Y, Kanematsu T. Treatment of liver cancer: current status and future prospectives. Gan to Kagaku Kyoho, 2000, 27(7):987-992
29 郭红梅. 原发性肝癌介入治疗前后血清 TNF-α,SIL-2R 水平检测的临床意义. Huaihai Med,2003,21(5):364-365
30 陈飞,侯芳玉. 肿瘤坏死因子与 SIDS. 国外医学· 免疫学分册,1992,4:179-189
31 Wu S,Boyer CM,Whitaker Rs,et al. Tuor necrosis factor for ovarian cancer; Monokine induction of tumor cell proliferation and tumor necrosis factor a expression. Cancer Res,1993,535:1939
32 Rey A, Klein B, Zagury D, et al. Diminished interleukin-2 activityproduction in cancer patients bearing solid tumors and its relationship with natural killer cells. Immunol Lett, 1983, 6(3):175~178
33 Matsunaga H, Kuwahara Y, Kusugami K, et al. Natural killer, lymphokine- activated killer and interferon-gamma producing activities of peripheral blood- and regional lymph node-mononuclear cells in 23 cases of colorectal cancer. Gastroenterol Jpn, 1988 ,23(5):527~533
34 Kusugami K, Matsuura T, Kawase T, et al. Interleukin 2 and interferon- gamma activities of mononuclear cells from regional lymph nodes in patients with gastric cancer. Gastroenterol Jpn, 1990 ,25(3):306~313
35 Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science, 1990 ,248(4961):1349~1356
36 Fischer JR,Schindel M,Bulzebruck H,et al. Long-term survival In small cell lung cancer patients is correlated with high interleukin-2 secretion at diagnosis.J Cancer Res Clin Oncol,2000,126:730~733
1 Gospdarowicz D,Abran Ram JA,Schillin J.Isolation and characterization of Avascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells.Proc Natl Acad Sci USA,1989,86:7311-7315
2 Ferrare N,Davis S T.Biology properties of the vascular endothelial growth factor familyof proteins.Endocr Rev,1997,18(1):4-25
3 Benjamin LE,Golijanin D,Itin A,et al.Selective ablation of i m mature blood vesselsin establish human tumors follows vascular endothelial growth factor withdraw.J Clin Invest,1999,103(2):159-165
4 Dvorak HF,Nagy JA,Feng D,et al.Vascular permeability factor/vascular endothelial growth factor and significance of microvascular permeability in angiogenesis.Curr Top Microbiol,1999,237(2):97-132
5 Jones A,Fujiyama C.Angiogenesis in urological malignancy prognostic indicator and therapeutic target.BJU International,1999,83(5):535-555
6 Folkman J . Clinical applications of research on angiogenesis〔see comments〕. N Eng1 J Med , 1995 ,333(26) :1757～1763
7 An FQ,Matsuda M,Fujii H,et al.Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma.J Cancer Res Olin Onco1,2000,126(3):153-160
8 Yamaguchi R,Yano H,lemura A,et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology, 1998, 28:68-77
9 Poon RT,Lau C,Yu WC,et al.High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma:a prospective study.Oncol Rep, 2004, 11(5): 1077-1084
10 柏林,吴永明,尹艳茹.肝癌患者血清 VEGF 的表达及临床意义. 第一军医大学分校学报, 2002,25(1):7-10
11 Brown LF , Berse B , Jackman R ,et al . Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol ,1995 ,26(11):86～91
12 Suzuki K, Hayashi N , Miyamoto Y, et al. Expression of vascular permeability factor/ vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res , 1996 , 56(13):3004-3009
13 Poon R T , Fan S T , Lo C M ,et al . Int rahepatic recurrence after curative resection of hepatocellular carcinoma. Long-term results of t reatment and prognostic factors . Ann Surg , 1999 , 229(1):216-222
14 Poon R T , Ng I O , Lau C , et al . Serum vascular endot helial growth factor predict s venous invasion in hepatocellular carcinoma : a prospective study . Ann Surg , 2001 , 233 (1):227-235
15 Goldstein HM, Wallnce S, Anderson JH, et al. Transcatheterem bolism of abdom inal tum ors Radiology, 1976, 120:539
16 葛宁灵,林芷英.影响介入治疗中晚期肝癌疗效的病理因素分析.国外医学·肿瘤学分册,1996,23:173-174
17 郭吉刚,郭顺林,杜富全,等.原发性肝癌 TACE 治疗前后血清 VEGF含量的变化.中华临床医学影像杂志,2003,14:181-183
18 Smith WL, Garavito RM, Dewitt DL, et al. Prostaglandin endoperoxide synthases cyclooxygenases-1 and-2. J Biol Chem, 1996, 271 (52): 33157-33160
19 Eberhart CE,Coffey RJ,Radhika A,et al.Up regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994,107:1183-1188
20 Koga H,Sakisaka S,Ohishe M,et al.Expression of cyclooxygenase-2 inhuman hepatocellular carcinoma:relevance to tumor dedifferentiation. Hepatology ,1999,29:688-696
21 Zhang BX, Chen XP, Yu HP, et al. Significance of cyclo-oxygenase-2 expression in human primary hepatocellular carcinoma. Chin J Exp Surg ,2004,21(3):305-306
22 Kondo M,Yamamoto H,Nagano H,et al.Increased expression if cox-2 in nontumor liver tissue is associated with shorter diseasefree survival in patients with hepatocellular carcinoma.Clin Cancer Res, 1999, 5:4005-4012 Murata H,Kawano S,Tsuji S,et al.Cyclooxygenase-2 over expression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol, 1996,94:51
1 李天晓,樊青霞,王瑞林.恶性肿瘤介入治疗学.郑州:河南科学技术出版社,2000:233
2 张天泽,徐光炜.肿瘤学. 第 2 版.天津:天津科学技术出版社, 2005:1602
3 Geschwind JF. Chemoembolization for hepatocellular carcinoma: where does the truth lie. J Vasc Interv Radiol,2002,13(10):991–994
4 张中华,陈衍智. 中药配合肝动脉化疗栓塞治疗肝癌临床观察. 实用肿瘤学杂志,2005,19(3):211-213
5 周炳刚,孙靖中,景生虹,等.中西医结合治疗中晚期肝癌 26 例疗效观察.新中医. 2002,3(11):37～38
6 邬晓东,金学军,刘淑梅,等.中药护肝软坚方对Ⅱ、Ⅲ期原发性肝癌肝动脉化疗栓塞增效减毒作用观察.北京中医药大学学报2003,26(1):67～68
7 俞世唐,斯艳阳,张为强,等.介入合并中医药治疗 362 例中晚期肝癌疗效评估.肿瘤研究与临床 2002,14(4):279～280
8 董明娥,白小娟,冯居秦,等.健脾益肾法配合介入治疗晚期肝癌36 例.陕西中医 2002,23(10):905
9 黄国贤,张蓓,张亚奇,等.中药防治肝癌介入治疗后肝储备功能损伤的临床研究.新医学 2003,34(4):221～222
10 何辉,王晓红,何东初.介入化疗联合复方苦参注射液治疗中晚期肝癌 30 例.中西医结合肝病杂志 2004,14(4):243～244
11 杨金祖,杨金坤,郑坚,等.中西医结合防治肝癌介入术后栓塞综合征的临床观察.上海中医药杂志 2004,38(9):11～12
12 姜新红,刘政,姚长清,等.健脾生血丸治疗肝癌介入术后不良反应的临床观察.中国中西医结合杂志 2003,23(11):866
13 汤钊酞,钦伦秀,孙惠川,等.肝癌复发转移的研究.中华普通外科杂志 2000,15(9):517～520
14 徐晓玉,严鹏科,陈刚,等.川穹嗪对小鼠肺癌血管生长和 VEGF表达的抑制.中国药理学通报 2004,20(2):151～154
15 冯刚,孔庆志,黄冬生,等.慧该仁注射液对小鼠移植性 s180 肉瘤血管形成抑制的作用.肿瘤防治研究 2004,31(4):229～230
16 林钧华,郭伟剑.健脾理气方联合介入疗法治疗肝癌远处转移 25 例临床观察.中医杂志 2005,46(l):26～28
17 陈宁.中晚期原发性肝癌中药应用规律.陕西中医,1995,16(2):87
18 Stockland AH, Walser EM, Paz-Fumagalli R, et al. Preoperative chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: influence of emergent versus elective procedures on patient survival and tumor recurrence rate. Cardiovasc Intervent Radiol,2007,30(5):888-893
19 徐伯平,张亚奇,李升平,等。化瘀健脾疏肝法对改善肝癌术后肝功能的影响。中国中西医结合杂志, 2001,21(10):742-743
20 姚树坤,殷飞,王娜。清肝化瘀方药对原发性肝癌患者的疗效及对细胞免疫功能的影响。临床荟萃, 2006,(18):1300-1302
1 吴孟超, 沈锋, 吴东. 原发性肝癌的外科治疗. 中华肝胆外科杂志. 2005, 11(2):75-77
2 Schmassmann A. Nonsurgical therapies for hepatocellular and cholangiocellular carcinoma. Swiss Surg. 1999, 5(3):116-121
3 Guan YS, Liu Y. Interventional treatments for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2006, 5(4):495-500
4 Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987,163:345-351
5 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003, 37:429-442
6 李桂杰, 周祝谦, 王连祥. 经肝动脉化疗栓塞术. 山东医药. 2006, 46(17):87-88
7 林含舜, 曹美萍, 李军苗. 肝动脉化疗栓塞治疗原发性肝癌. 实用医学杂志. 2003, 19(10):1178-1179
8 Goldstein HM, Wallace S, Anderson JH, et al. Transcatheter occlusion of abdominall tumors. Radiology. 1976, 120(3):539-545
9 O’Suilleabhain CB, Poon RT, Yong JL, et al. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg. 2003, 90(3):325-331
10 Barone M, Ettorre GC, Ladisa R, et al. Transcatheter arterial chemoembolization (TACE) in treatment of hepatocelluar carcinoma. Hepatogastroenterology. 2003, 50(49):183-187
11 Yamada R, Kishi K, Sato M, et al. Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer. World J Surg. 1995, 19(6):795-800
12 Lo CM, Ngan H, Tso WK. Randomized controlled trial of tansarterial lipiodol chemoembolization for unresectable hepatocellular carcinama.Hepatology. 2002, 35(5):1164-1171
13 Gunji T, Kawauchi N, Akahane M, et al. Long-term outcome of transcatheter arterial chemoembolization with autologous blood clot for unresectalbe hepatocellular carcinoma. Int J Oncol. 2002, 21(2):427-432
14 孙健, 张彤, 王捷. 肝癌的TACE治疗. 国外医学外科学分册. 2005, 32(2):84-88
15 Trinchet JC, Ganne-Carrie N, Beangrand M. Intraarterial chemoembolization in patients with hepaocellular carcinoma. Hepatogastro Enterology. 1998, 45(Suppl 3):1242-1243
16 Ochiai T, Sonoyama T, Hironaka T, et al. Hepatectomy with chemoembolization for treatment of hepatocellular carcinoma. Hepatogastroenterology. 2003, 50(51):750-755
17 Hanazaki K, Kajikawa S, Shimozaxa N, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 2000, 191(4):381-388
18 Tanaka K, Shimada H, Togo S, et al. Use of tanscatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Hepatogastroenterology, 1999, 46(2):1083-1088
19 Asahara T, Itamoto T, Katayam K, et al. Adjuvant hepatic arterial infusion chemotheraphy after radical hepatectomy for hepatocellular carcinoma-results of long-term follow-up. Hepatogastroenterology. 1999, 46(2):1042-1048
20 Saccheri S, Lovaria A, Sangiovanni A, et al. Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J Vasc Interv Radiol. 2002, 13(10):995-999
21 Li JQ. Clinical and laboratory study on cut-margin of hepatocellular carcinoma. J Gastroenterol Hepatol. 2000, 15(Suppl):157
22 Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment andprongostic factors. Ann Surg. 1999, 229(2):216-222
23 Li YH, Wang CS, Liao LY, et al. Long-term survival of Taicanese patients with hepatocellular carcinoma after combination therapy with tanscatheter arterial chemoembolization and percutaneous ethanol injection. J Formos Med Assoc. 2003, 102(3):141-146
24 Bloomston M, Binitie O, Fraiji E, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy. Am Surg. 2002, 68(9):827-831
25 Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolizal followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003, 9(6):557-563
26 Ishikura S, Ogino T, Furuse J, et al. Radiotherapy after tanscatheter arterial chemoembolization for patient with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol. 2002, 25(2):189-193
27 Shiomi M, Kamiya J, Naqino M, et al. Hepatocellular carcinoma with biliary tumor thrombi: aggressive operative approach after appropriate preoperative management. Surgery. 2001, 129(6):692-698
28 Hu J, Pi Z, Yu MY, et al. Obstructive jaundice caused by tumor embolization from hepatocellular carcinoma. Am Surg. 1999, 65(5):406-410
29 Fukuda S, Okuda K, Imamura M, et al. Surgical resection combined with chemothraphy from advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery. 2002, 131(3):300-310
30 高宗恩, 张承勋, 庞闽厦, 等. 肝癌供血的特点及其在介入治疗中的意义. 2001, 9(12):1449-1451
31 茅国新, 于志坚, 张一心, 等. 经导管肝动脉和B超引导下经细针门静脉双重化疗栓塞治疗原发性肝癌. 中华肿瘤杂志. 2002, 24(4):391-393
32 Ng KK, Poon RT. Current treatment strategy for hepatocellular carcinoma. Saudi Med J. 2007, 28(9):1330-1338
33 蔡东顺, 贾朝阳. 经肝动脉栓塞化疗与无水乙醇消融术联合治疗小肝癌. 现代医用影像学. 2005, 14(5):220-221
34 胡大武, 陈君辉, 伍海翔, 等. 肝动脉化疗栓塞结合经皮肝穿刺瘤内注射醋酸治疗原发性肝癌的疗效观察. 介入放射学杂志. 2004, 13(1):53-55
35 江怡, 顾庆. 肝动脉栓塞化疗和超声引导下介入综合治疗肝肿瘤. 上海医学影像. 2002, 11(3):228-229,231
36 曹玮, 王执民, 张洪新. 介入性热化疗治疗肝癌. 医师进修杂志. 2004; 27(3):55-56
37 Hui KM. Current approaches in the transcriptional-guided gene therapy of human hepatocellular carcinoma. Curr Opin Mol Ther. 2007; 9(4):378-384
38 官泳松, 孙龙, 周翔平, 等. 重组人p53腺病毒基因局部注射联合肝动脉化疗栓塞治疗原发性肝癌. 世界华人消化杂志. 2005, 13(1):125-127
39 Chan AO, Yuen MF, Hui CK, et al. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002, 94(6):1747-1752
40 肖承江, 郑丽吟, 蒋晓红. 肝动脉栓塞化疗对肝损害的观察(附100例分析). 中华放射学杂志. 1997, 31(11):777-779
41 施海彬, 冯耀良. 合并门静脉癌栓的原发性肝癌的影像学特征及其介入治疗. 临床放射学杂志. 1997, 16(2):111-113
42 Katsumori T, Fujita M, Takahashi T, et al. Effective segmental chemoembolization of advanced hepatocellular carcinoma with tumor thrombus in the portal vein. Cardiovasc Intervent Radiol. 1995, 18(4):217-221
43 陈晓明, 罗鹏飞, 邵培坚, 等. 肝癌节段性栓塞化疗与常规栓塞化疗的比较研究. 中华放射学杂志. 2000, 34(4):271-273
44 骆训武, 蓝琳, 张亚力, 等. 腺苷蛋氨酸在肝动脉插管栓塞化疗术后的护肝作用. 中华消化杂志. 2002, 22(11):680
45 Okuhama Y, Shiraishi M, Higa T, et al. Protective effects of ulinastatin against ischemia-reperfusion injury. J Surg Res. 1999,82(1):34-42
46 Kobayashi H, Shinohara H, Gotho J, et al. Anti-metastatic therapy byurinary trypsin inhibitor in combination with an anti-cancer agent. Br J Cancer. 1995, 72(5):1131-1137
47 叶华, 王捷, 张建龙. 乌司他丁在肝动脉栓塞化疗中的应用. 中华肝胆外科杂志. 2002, 8(4):249-250
48 陈徐贤, 张蓓, 张亚奇, 等. 中药防治肝癌化疗栓塞术后肝储备功能损害的临床研究. 癌症. 2002, 21(5):547-549
1 Nq KK, Poon RT. Current treatment strategy for hepatocellular carcinoma. Saudi Med J. 2007, 28(9):1330-1338
2 Chen XX, Zhang B, Zhang YQ, et al. Treatment of hepatic functional reserve injury after TACE in hepatocellular carcinoma with Chinese herbal medicines. Ai Zheng. 2002, 21(5):547-549
3 Feng YL, Ling CQ, Li B. Clinical study on integrative medicine for preventing and treating post-transcatheter arterial chemoembolization. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005, 25(6):534-536
4 陈徐贤, 张蓓, 张亚奇, 等. 健脾活血中药对肝癌肝动脉化疗栓塞术后综合征的影响. 新中医. 2006, 38(7):57-58
5 肖承江, 郑丽吟, 蒋晓红. 肝动脉栓塞化疗对肝损害的观察(附100例分析). 中华放射学杂志. 1997, 31(11):777-779
6 狄灵,杨成志,刘润侠,等. 参芪扶正注射液治疗原发性肝癌栓塞化疗综合征的临床研究. 现代肿瘤医学. 2004, 12(5):473-474
7 李仲启, 傅汉中, 魏国强, 等. 参麦注射液配合肝动脉化疗栓塞治疗肝癌临床疗效观察. 中国肿瘤临床与康复. 2005, 12(1):64-65
8 李杰,孙桂芝. 肝康冲剂配合肝动脉介入治疗原发性肝癌的临床研究. 医学理论与实践. 1998, 11(8):341-343
9 李翠静, 许祖闪. 肝动脉化疗栓塞后免疫或中药综合治疗肝癌108例观察. 肿瘤防治杂志. 2003, 10(11):1209-1210
10 于有涛,申宝忠. 蛇莲胶囊对介入治疗原发性肝癌患者免疫功能的影响. 中国肿瘤. 2003, 12(1):59-60
11 张绪平, 易玉海, 金鹏, 等. 恶性肿瘤介入疗法常用中药制剂抗癌机制国内研究概况. 实用医药杂志. 2006, 23(2):232-234
12 程剑华, 吴万垠, 刘伟胜, 等. 莪术油肝动脉灌注栓塞治疗原发性肝癌
17 例. 世界华人消化杂志. 1999, 7(1):92
13 冯敢生, 郑传胜, 张彦舫. 中药白芨胶栓塞治疗肝癌的应用研究. 中国肿瘤. 1997, 6(4):10-12
14 凌昌全, 李琦. 中药经肝动脉介入治疗原发性肝癌的现状、存在问题及前景. 中医杂志. 2002, 43(1):69-71
15 贺用和, 韩静. 中药制剂在原发性肝癌肝动脉化疗栓塞术治疗中的应用研究进展. 中国中医药信息杂志. 2006, 13(12):95-97
16 顾伟, 韩克起. 中医药在肝癌介入治疗中的临床应用. 肝脏. 2003, 8(4):59-61
17 陆浩, 周健生, 徐逊, 等. 康莱特注射液联合肝动脉化学栓塞治疗中晚期原发性肝癌疗效观察. 中原医刊. 2006, 33(23):3-4
18 钱军, 秦叔逵. 抗癌新药——榄香烯的药理及临床. 中国肿瘤临床. 1996, 23(6):453-455
19 周洪语, 侯菊生, 罗其中. 榄香烯抗肿瘤作用机制的研究进展. 中国肿瘤临床. 2000, 27(5):392-394
20 梁宇闯, 高珩, 林坚, 等. 经肝动脉插管灌注榄香烯乳治疗中晚期肝癌的观察. 右江民族医学院学报. 2004, 26(2):200-201
21 崔永安, 左小东, 秦叔逵, 等. 华蟾素抗肿瘤作用的临床研究. 江苏临床医学杂志. 2002, 6(5):505-508
22 孙中杰, 潘承恩, 王国俊. 华蟾素配合 TACE 治疗肝癌的临床观察. 肿瘤防治研究. 2002, 29(1):67-68
23 陈庆强, 王昌俊, 卢秋红. 羟基喜树碱肝动脉栓塞及灌注治疗晚期原发性肝癌. 中国肿瘤临床. 2000, 27(8):620-621
24 陈杰, 张先稳. 艾迪注射液对荷瘤小鼠的抗瘤效应及免疫调节作用. 徐州医学院学报. 2005, 25(3):208-210
25 袁洪新, 于志坚. 艾迪注射液联合肝动脉介入治疗原发性肝癌. 临床肿瘤学杂志. 2005, 10(1):64-66
26 李琦, 范忠泽, 李先茜, 等. 去甲斑蝥素微球介入治疗大鼠肝癌疗效及其机制研究. 中西医结合学报. 2006, 4(4):378-383
27 杨林, 孟茂斌, 官泳松, 等. 中医中药在肿瘤介入治疗中的应用. 2006, 21(3):646-647
28 司维柯, 李鹏, 王源, 等. 苦参碱抗人肝癌细胞株HepG2的作用及其机制研究. 国外医学临床生物化学与检验学分册. 2003, 24(5):288-290
29 王俊学, 王国俊, 蔡雄, 等. 氧化苦参碱及甘草甜素对小鼠肝细胞凋亡的影响. 第二军医大学学报, 1999, 20(4):222-224
30 许相儒, 蒋纪恺. 苦参及其生物碱抗肿瘤活性研究进展. 中国中西医结合杂志. 1998, 8(5):314-316
31 梁建新, 曾文铤, 朱科伦, 等. 苦参碱联合介入化疗栓塞治疗中晚期肝癌疗效观察. 广州医药. 2005, 36(3):45-47
32 莉萍, 蒋纪恺, 谭安, 等. 苦参碱对K562细胞端粒酶活性细胞周期的影响. 中华肿瘤杂志. 1998, 20(5):328
33 于绍军, 朱英杰, 高峰. 岩舒注射液治疗晚期肝癌临床观察. 华北煤炭医学院学报. 2000, 2(5):552
34 朱晓锋, 李国安. 岩舒注射液联合介入化疗栓塞治疗中晚期肝癌的研究. 现代中西医结合杂志. 2006, 15(4):431-432
35 Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [ stronger neo-minophagen C (SNMC) ] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology. 2002, 62(11):94-100
36 Rossi T, Castelli M, Zandomeneghi G, et al. Selectivity of action of glycyrrhizin derivatives on the growth of MCF27 and HEP22 cells. Anticancer Res. 2003, 23(5A):3813-3818
37 Miyaji C, Miyakawa R, Watanabe H, et al. Mechanisms underlying the activation of cytotoxic function mediated by hepatic lymphocytes following the administration of glycyrrhizin. Int Immunopharmacol. 2002, 2(8):1079-1086
38 Lu W, Li Y, He X, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patientswith cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Hepatogastroenterology. 2003, 50(54):2079-2083
39 张伟, 叶孟, 金伟. 复方甘草酸苷在原发性肝癌TACE术后的应用. 浙江中西医结合杂志. 2006, 16(4):210-211
40 袁国荣. 鸦胆子油乳联合介入化疗为主治疗局部晚期非小细胞肺癌40例 临 床 研 究 —— 附 单 用 介 入 化 疗 38 例 对 照 . 浙 江 中 医 杂 志 . 2005,15(1):13-15
41 马杰津. 抗癌药物鸦胆子的研究进展. 医学文选. 2001, 20(3):378-379
42 李英, 徐功立, 李颖, 等. 鸦胆子油乳诱导白血病U937细胞凋亡的实验研究.中华血液学杂志. 2004, 25(6):381-382
43 Kleibl Z, Raisova M, No Votny J, et al. Apoptosis and its importance in the development and therapy of tumors. Sb Lek. 2002, 103(1):1-3
44 李笑弓, 向勋义, 李建功, 等. 鸦胆子油静脉乳对人肾癌影响的实验研究. 临床泌尿外科杂志. 1998, 13(2):82-87
45 李文志, 冯汝就. 鸦胆子油乳注射液联合TACE治疗原发性肝癌的临床疗效观察. 中药材. 2006, 29(6):632-633
46 吴万垠, 励雁峰. 健脾理气方对人乙型肝炎病毒转基因小鼠不同时相血清黄曲霉素B1-白蛋白加成物水平的影响. 中西医结合肝病杂志. 1996, 6(2):17-18
47 卜平, 陈齐鸣. 实脾法防治TAE胃肠损害并发症的临床研究. 中西医结合肝病杂志. 1996, 6(4):16-17
48 陈群雄. 参三金粉对肝癌介入化疗后的作用. 中医药研究. 1998, 14(3):34-35